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ABSTRACT 
 
Peptidoglycan (PG) is the major structural component of the bacterial cell wall.  Bacteria have 
autolytic PG hydrolases that allow the cell to grow and divide.  A well-studied group of PG 
hydrolase enzymes are the bacteriophage endolysins.  Endolysins are PG degrading proteins 
that allow the phage to escape from the bacterial cell during the phage lytic cycle. The 
endolysins, when purified and exposed to PG externally, can cause "lysis from without".  
Numerous publications have described how this phenomenon can be used therapeutically as an 
effective antimicrobial against certain pathogens.  Endolysins have a characteristic modular 
structure, often with multiple lytic and/or cell wall binding domains.  They degrade the PG with 
glycosidase, amidase, endopeptidase, or lytic transglycosylase activities, and have been shown 
to be synergistic with fellow PG hydrolases or a range of other antimicrobials.   Due to the co-
evolution of phage and host, it is thought they are much less likely to invoke resistance.  
Recently, endolysin engineering has opened a range of new applications for these proteins from 
food safety to environmental decontamination to more effective antimicrobials that are believed 
refractory to resistance development.  To put the phage endolysin work in a broader context, 
this chapter includes relevant studies of other well characterized PG hydrolase antimicrobials. 
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I.  Introduction  
 
The bacterial peptidoglycan (PG) is a protective barrier as well as a structural component of the 
bacterial cell wall that defines its shape.  Notably, the PG supports the internal turgor pressure 
that is essential for survival of the prokaryotic cell.  PG hydrolase generically describes a wide 
range of lytic enzymes that act upon the bacterial PG and can be classified into several groups 
based on their origin.  An "autolysin" is a PG hydrolase that is produced and regulated by the 
bacterial cell for growth, division, maintenance, and repair of the PG.  In contrast, an "exolysin" 
is an enzyme secreted by a bacterial cell that functions to lyse the PG of a different strain or 
species occupying the same ecological niche.  One of the most studied bacterial exolysin is 
lysostaphin, a PG hydrolase secreted by Staphylococcus  simulans  that cleaves the S. aureus 
PG, but does not harm the S. simulans  PG (Schindler and Schuhardt, 1964).  In addition to 
bacterial exolysins, eukaryotic cells can secrete their own exolysins.  For example, lysozyme 
found in human saliva and tears is a eukaryotic exolysin that is part of the innate immune 
system providing protection against bacterial invasion.    
 
PG hydrolases are also used extensively by bacteriophage (phage), for infection and/or release 
from a bacterial host.  Particle-associated PG hydrolases can produce “lysis from without”, a 
term used to describe bacterial lysis in the absence of the full lytic infection cycle, as first 
described by Delbrück in 1940 (Delbruck, 1940).  Recent work by Moak and Molineux 
demonstrated that PG hydrolases were associated with numerous phage particles infecting 
either Gram-negative or Gram-positive bacteria (Moak and Molineux, 2004).  These lytic 
structural proteins, that are mostly tail-associated, cause localized degradation of the cell wall to 
enable infection of the bacterial host.  Alternatively, phage encode PG hydrolases that, along 
with holins, are part of the lytic cassette.  Holins are produced during the late stages of a phage 
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infection cycle to perforate the inner bacterial membrane, thus allowing the PG hydrolases that 
have accumulated in the cytoplasm to gain access to the PG.  The result is bacterial lysis and 
release of progeny phage completing the infection cycle (Young, 1992).  Because these PG 
hydrolases lyse "from within", they are referred to as "endolysins", or simply "lysins".   
 
Significantly, exogenous addition of a phage endolysin or a bacterial exolysin to a susceptible 
host can be exploited to produce lysis from without due to the high osmotic pressure within the 
cell (~5 atmospheres for Gram-negative organisms and up to 50 atmospheres for Gram-positive 
organisms (Seltman and Holst, 2001)).  The use of purified phage endolysins or other naturally 
occurring PG hydrolases as antimicrobial agents against Gram-positive pathogens is the theme 
of this chapter [for prior reviews, see (Callewaert et al., 2010;Fischetti, 2005;Fischetti et al., 
2006;Hermoso et al., 2007;Loessner, 2005)].  Due to the presence of an outer membrane in 
Gram-negative bacteria, an exogenously added PG hydrolase will usually not gain access to the 
PG without surfactant or some other mechanism to translocate the protein across the outer 
membrane.  Nonetheless, reports are beginning to emerge in the literature that describe fusions 
of Gram-negative endolysins that will lyse these pathogens from without, which will be 
discussed at the end of this chapter.   
 
II.  Peptidoglycan Structure    
 
As the name implies, the peptidoglycan is a three dimensional lattice of peptide and glycan 
moieties.  A polymer of alternating N-acetylmuramic acid (MurNAc) and N-acetylglucosamine 
(GlcNAc) residues coupled by β(1→4) linkages comprises the “glycan” component of the PG 
(Fig. 1).  This polymer displays little variation between bacterial species (for review see 
(Schleifer and Kandler, 1972)).  The glycan polymer is in turn covalently linked to a short stem 
peptide through an amide bond between MurNAc and an L-alanine, the first amino acid of the 
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“peptide” component.  The remainder of the stem peptide is composed of alternating L- and D-
form amino acids that are fairly well conserved in Gram-negative organisms, but is variable in 
composition for Gram-positive organisms.  For many Gram-positive organisms, the third residue 
of the stem peptide is L-lysine, which is crosslinked to an opposing stem peptide on a separate 
glycan polymer through an interpeptide bridge, the composition of which varies between 
species.  For example, the interpeptide bridge of S. aureus is composed of pentaglycine 
(depicted in Fig. 1) whereas the interpeptide bridge of Streptococcus pyogenes is di-alanine.  In 
Gram-negative organisms and some genera of Gram-positive bacteria (i.e., Bacillus and 
Listeria), a meso-diaminopimelic acid (mDAP) residue is present at position number three of the 
stem peptide instead of L-lysine.  In these organisms, mDAP directly crosslinks to the terminal 
D-alanine of the opposite stem peptide (i.e. no interpeptide bridge).  Whether an interpeptide 
bridge is present or not, a transpeptidation reaction joining opposing stem peptides gives rise to 
the three dimensional lattice that is the hallmark of the bacterial peptidoglycan.  Notably, several 
antibiotics target the transpeptidation reaction because the crosslinking is so critical to proper 
formation and integrity of the cell wall and survival of the organism. 
 
III.  Endolysin Activities and Structure  
 
A.  Enzymatic activities   
 
Due to the moderately conserved overall structure of the PG, there are limited types of covalent 
bonds that are available for cleavage by endolysins and other PG hydrolases (Fig. 1).  In 
general, there are four mechanistic classes associated with PG hydrolases: glycosidase, 
endopeptidase, a specific amidohydrolase, and lytic transglycosylase.  One type of glycosidase, 
known as an N-acetylglucosaminidase, cleaves the glycan component of the PG on the 
reducing side of GlcNAc (Fig. 1A).  This type of activity is frequently found in autolysins, such as 
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AltA from Enterococcus faecalis (Mesnage et al., 2008) or AcmA, AcmB, AcmC, and AcmD from 
Lactococcus lactis (Steen et al., 2007).  However, with the exception of the streptococcal 
LambdaSa2 endolysin (Pritchard et al., 2007), this activity has not been associated with phage 
endolysins.  A second type of glycosidic activity is an N-acetylmuramidase, which cleaves the 
glycan component of the PG on the reducing side of MurNAc (Fig. 1B).  This activity is 
commonly referred to as a “muramidase” or “lysozyme” and is frequently found in autolysins, 
exolysins, and phage endolysins, including the pneumococcal Cpl-1 endolysin (Garcia et al., 
1987) and the streptococcal B30 endolysin (Pritchard et al., 2004).   
 
The second class of PG hydrolases is an N-acetylmuramoyl-L-alanine amidase, a specific 
amidohydrolase that cleaves a critical amide bond between the glycan moiety (MurNAc) and the 
peptide moiety (L-alanine) of the PG (Fig. 1C)  This activity is more often associated with 
bacteriophage endolysins than autolysins or exolysins.  The reasons for this are not clear.  
However, because hydrolysis of this bond separates the glycan polymer from the stem peptide, 
such activity is speculated to be more destabilizing to the PG than hydrolysis of other bonds and 
may be evolutionarily favored by bacteriophage that require rapid lysis of host cells for 
dissemination of progeny phage.  This activity has been demonstrated for the amidase domain 
of the staphylococcal phage Ф11 endolysin (Navarre et al., 1999), the phage K endolysin, LysK 
(Becker et al., 2009a;Donovan et al., 2009), and the Listeria phage endolysins Ply511 
(Loessner et al., 1995b) and PlyPSA (Korndorfer et al., 2006).   
 
The third class of PG hydrolases is that of an endopeptidase (i.e. protease), which cleaves 
peptide bonds between two amino acids.  This cleavage may occur in the stem peptide, such as 
the listerial Ply500 and Ply118 L-alanyl-D-glutamate endolysins (Loessner et al., 1995b), or in 
the interpeptide bridge, such as the staphylococcal Ф11 D-alanyl-glycyl endolysin (Navarre et 
al., 1999) or the lysostaphin exolysin (Fig. 1D-G).    
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The fourth and final class of PG lytic enzymes is the lytic transglycosylase.  By definition, these 
enzymes are not true "hydrolases" because they do not require water to catalyze PG cleavage.  
They are very similar to muramidases in that they cleave the β(1→4) linkages between N-
acetylmuramyl and N-acetylglucosaminyl residues of the PG (Fig. 1B), but they form a 1,6 
anhydromuramyl residue during glycosidic cleavage and thus belong to a different mechanistic 
class than the lysozymes (Holtje and Tomasz, 1975).  The  e ndolys in (Taylor and 
Gorazdowska, 1974) and the gp144 endolysin from the ΦKZ bacteriophage (Paradis-Bleau et 
al., 2007) were both biochemically confirmed to be lytic transglycosylases.  
 
B.  Biochemical determination of endolysin specificity  
 
Numerous studies have investigated the specificity of endolysins by assaying the cleavage sites 
on purified PG (Dhalluin et al., 2005;Fukushima et al., 2007;Fukushima et al., 2008;Loessner et 
al., 1998;Navarre et al., 1999;Pritchard et al., 2004).  Classic biochemical methods, such as the 
Park-Johnson method, can be used to measure an increase of reducing sugar moieties as an 
indication of glycosidase activity by reduction of ferricyanide to ferrocyanide (Park and Johnson, 
1949;Spiro, 1966).  A variation of the method using sodium borohydride to reduce digested cell 
wall samples (Ward, 1973)  has also been used frequently (Deutsch et al., 2004;Dhalluin et al., 
2005;Scheurwater and Clarke, 2008;Vasala et al., 1995).  
Endopeptidase or L-alanine amidase activities can be observed by an increase of free amine 
groups as measured by a trinitrophenylation reaction originally described by Satake (Satake et 
al., 1960) and modified by Mokrasch (Mokrasch, 1967).   N-terminal sequencing of digestion 
products (i.e., Edman degradation) can also reveal cleavage sites of a PG hydrolase 
possessing an endopeptidase activity (Navarre et al., 1999;Pritchard et al., 2004).  Alternatively, 
digestions products can be labeled with FDNB (1-Fluoro-2,4-dinitrobenzene) followed by HCl 
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hydrolysis and Reverse Phase-HPLC (Fukushima et al., 2007).  HPLC peaks can be analyzed 
by MS and resulting fragment ions by MS-MS analysis (Fig. 2) (Becker et al., 2009a;Fukushima 
et al., 2008;Navarre et al., 1999)).  Many of the techniques described above were used in an 
elegant series of experiments that showed the streptococcal phage B30 endolysin contains both 
a glycosidase and an endopeptidase activity within the same protein (Baker et al., 
2006;Pritchard et al., 2004).   
 
C.  Confusion over historical endolysin nomenclature  
 
The assignment of nomenclature to endolysins has been less than ideal.  Decades ago, 
endolysins were simply referred to as “lysozymes”, a generic term often applied to PG 
hydrolases despite a lack of biochemical evidence characterizing their enzymatic activity.  
Unfortunately, many of these older designations persist to this day.  The endolysin of the T7 
bacteriophage continues to be called the “T7 lysozyme” in the literature despite experimental 
evidence dating back to 1973 showing that it is actually an N-acetylmuramoyl-L-alanine 
amidase rather than an N-acetylmuramidase (i.e. lysozyme) (Inouye et al., 1973).  Likewise, the 
λ endolysin was shown to be a lytic transglycosylase 35 years ago, but the “lysozyme” moniker 
continues in the current literature.  Another challenge is the generic classification of many 
endolysins simply as “amidases”, which is ubiquitously used to describe both N-
acetylmuramoyl-L-alanine amidases and endopeptidases, the latter being exclusive to 
hydrolysis of an amide bond between two amino acids.  To further complicate this issue, a 
protein family called CHAP (cysteine, histidine-dependent amidohydrolase/peptidase) has 
emerged as a common domain found in bacteriophage endolysins (Bateman and Rawlings, 
2003).  Experimental evidence shows the CHAP domain of the group B streptococcal B30 lysin 
is a D-alanyl-L-alanyl endopeptidase (Pritchard et al., 2004) whereas the CHAP domain of the 
group A streptococcal PlyC lysin is an N-acetylmuramoyl-L-alanine amidase (Fischetti et al., 
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1972;Nelson et al., 2006).  Finally, many endolysin catalytic domains are alleged to possess a 
particular activity based exclusively on limited homology to another endolysin domain with a 
putative function.  When actual experiments are conducted to determine cleavage specificities, 
the results are often contrary to the function assigned by bioinformatic analysis.  For example, in 
silico analysis suggests the streptococcal endolysins λSa1 and λSa2 contain N-acetylmuramoyl-
L-alanine amidase activities.  However, utilizing electrospray ionization mass spectrometry, 
Pritchard et. al., not only showed an absence of N-acetylmuramoyl-L-alanine amidase activity, 
but provided evidence that these enzymes function as D-glutaminyl-L-lysine endopeptidases 
(Pritchard et al., 2007).   Clearly, more rigorous biochemical characterization of bacteriophage 
endolysins will help to better define and predict the catalytic classes of these enzymes. 
 
D. Endolysin modular structure  
 
D.1. Gram-negative endolysin structure 
 
The Gram-negative PG, which lies subjacent to the outer membrane in the periplasmic space, is 
relatively thin and undecorated by surface proteins or carbohydrates.  Consequently, most 
lysins from phage that infect Gram-negative hosts are single domain globular proteins that are 
typically comprised of only a single catalytic domain and have a mass of 15 to 20 kDa.  
However, two Gram-negative phage endolysins (Pseudomonas phage endolysins KZ144 and 
EL188) were recently shown to harbor both a lytic domain and an N-terminal cell wall binding 
domain (CBD) (Briers et al., 2007). The first 83 amino acids of KZ144 have been shown to be 
sufficient for high affinity binding to Pseudomonas aeruginosa cell walls (Briers et al., 2009).   
Moreover, this domain was shown to bind to  Gram-negative PG from all species on which it 
was tested (after chemical treatments to remove the outer membrane) (Briers et al., 2007). 
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D.2. Gram-positive endolysin structure 
 
In contrast to the Gram-negative bacteria, Gram-positive organisms contain no protective outer 
membrane, but rather have a much thicker (up to 40 layers) PG layer that is highly crosslinked 
and decorated with surface carbohydrates and proteins.  Endolysins from Gram-positive 
infecting bacteriophage typically utilize a modular design (Diaz, et al.,1990), having one or more 
catalytic domains and a CBD that recognizes epitopes on the surface of susceptible organisms, 
often giving rise to strain- or near-species-specific binding (Schmelcher et al., 2010).  Typically, 
a flexible interdomain linker sequence connects the catalytic domain(s) to the CBD (Korndorfer 
et al., 2006).  
 
Nearly all Gram-positive endolysins and autolysins are the products of single genes, though 
group I introns are often found within these genes and have been reported for Streptococcus 
(Foley et al., 2000) and Staphylococcus (Becker et al., 2009b;Kasparek et al., 2007;O'Flaherty 
et al., 2004).  The gene encoding the streptococcal C1 phage endolysin, PlyC, was originally 
believed to contain an intron (Nelson et al., 2003), but was later shown to be synthesized from 
two genes.  This enzyme is composed of a gene product, PlyCA, which contains the catalytic 
domain and eight identical copies of a second gene product, PlyCB, which harbors the CBD 
(Nelson et al., 2006).  To date, no other multimeric lysin has been identified and the implications 
for a multi-gene, heterononomer are not abundantly clear.  Nonetheless, nanogram quantities of 
PlyC can achieve ~7 log killing of streptococcal cells within seconds, making PlyC several 
orders of magnitude more active than any other PG hydrolase ever described (Nelson et al., 
2001). 
 
The three-dimensional crystal structure of known endolysin lytic domains was reviewed recently 
(Hermoso et al., 2007).  A very complete discussion of the PG hydrolase endopeptidase 
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activities and their active site structure was also recently presented by Bochtler and colleagues 
(Firczuk and Bochtler, 2007).  Interdomain linker sequences between the catalytic and CBD 
domains can vary in size and can impart an inherent flexibility to these proteins making 
crystallography of full-length endolysins challenging.  Many attempts have yielded only the 
structures of individual catalytic domains or isolated CBDs (Korndorfer et al., 2008;Low et al., 
2005;Porter et al., 2007;Silva-Martin et al., 2010).   Only a few full-length structures have 
become available, including PlyPSA, a listerial N-acetylmuramoyl-L-alanine amidase 
(Korndorfer et al., 2006), and Cpl-1, a pneumococcal N-acetylmuramidase (Hermoso et al., 
2003).  Remarkably, both structures reveal extreme compartmentalization displayed by the 
individual domains (Bustamante et al., 2010;Monterroso et al., 2008).  
 
D.3. Domain conservation of Gram-positive endolysins 
 
Alignment of conserved PG hydrolase domain sequences is available in public data sets (e.g. 
Pfam; http://pfam.jouy.inra.fr/).  Such comparisons have identified numerous conserved 
domains shared across many genera for both binding to the bacterial surface (CBDs) and 
catalysis of the PG (lytic domains).  Through a limited number of site-directed mutagenic 
studies, invariant amino acid residues conserved in domain sequences have been identified.  
Primarily histidine residues have been identified, that when mutated, can destroy the hydrolytic 
activity of the M23 endopeptidase domain (Fujiwara et al., 2005) or the  cysteine, histidine-
dependent amidohydrolases/peptidases (CHAP) domain (Bateman and Rawlings, 2003;Huard 
et al., 2003;Nelson et al., 2006;Pritchard et al., 2004;Rigden et al., 2003).  
 
Using public data sets and Pubmed, we have attempted to compile the known PG hydrolase 
sequences for each of three genera Enterococcus, Staphylococcus, and Streptococcus.  These 
protein structures are collated in Figs. 3, 4 and 5.  This summary sheds light on the degree of 
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domain conservation and the range of lytic protein domain organization within and between 
these closely related genera.  Within each genus, the endolysins have been collated into groups 
based on protein architecture and sequence homology.  The group members are listed in 
Tables 1, 2 and 3.  Each group has mostly > 90% within group identity at the amino acid residue 
level, and between group identities is mostly less than 50%.  There are also stand-alone lysins 
with no apparent homologues yet reported.  There has not been an attempt to assign a  species 
to each of the endolysins within a genus, due to the high frequency of mobile genetic elements 
and lateral gene transfer that is known to exist within each  (Lindsay, 2008;Palmer et al., 
2010;Rossolini et al., 2010).    Each of the domains listed in Figs. 3, 4 and 5 can be found in 
public data sets describing conserved domains (PFAM : http://pfam.sanger.ac.uk/ or NCBI 
conserved domain database (CDD): http://www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml). 
 
D.4. Endolysins with multiple catalytic domains 
 
Although it is well established that single domain endolysins can lyse the target pathogen (Sanz 
et al., 1996), there are numerous endolysins that harbor two short lytic domains (~100-200 
amino acids), each encoding a different catalytic activity.  A few examples of dual domain 
endolysins for which the cut sites are known include: 1) the staphylococcal Ф11 endolysin has 
both N-acetylmuramoyl-L-alanine amidase and D-alanyl-glycyl endopeptidase catalytic activities 
(Navarre et al., 1999), 2) the group B streptococcal lysin B30 was shown to have both N-
acetylmuramidase and a D-alanyl-L-alanyl endopeptidase catalytic activity on purified PG 
(Pritchard et al., 2004), 3) the streptococcal λSa2 phage endolysin has an N-terminal D-
glutaminyl-L-lysine endopeptidase activity and an  N-acetylglucosaminidase C-terminal domain 
(Pritchard et al., 2007), and 4) LysK is the staphylolytic phage K endolysin featuring a CHAP 
endopeptidase and an amidase domain but shares less than 50% amino acid sequence identity 
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with the Ф11 endolysin despite cleaving identical bonds on purified staphylococcal PG (Becker 
et al., 2009a). 
 
The presence of two catalytic domains does not necessarily indicate that both are equally active 
when lysing from without.  The streptococcal λSa2 phage endolysin D-glutaminyl-L-lysine 
endopeptidase activity domain was shown via deletion analysis to be responsible for almost all 
of the hydrolytic activity of this enzyme whereas its N-acetylglucosaminidase domain was found 
to be almost devoid of activity (Donovan and Foster-Frey, 2008).   The same dominant domain 
phenomena was demonstrated with both deletion and site-directed mutational analysis for the 
streptococcal B30 phage endolysin [99% identical to PlyGBS (Cheng and Fischetti, 2007)].  The 
N-terminal D-alanyl-L-alanyl endopeptidase domain is responsible for virtually all of the in vitro 
streptolytic activity and the glycosidase domain is silent in these assays (Donovan et al., 2006b) 
despite both domains showing catalytic activity on purified PG (Pritchard et al., 2004).   There is 
no current explanation for this recurrent pattern of a highly conserved lytic domain that is 
seemingly inactive (when applied externally) in these unrelated streptococcal proteins (λSa2 vs. 
B30).  These two proteins share little in the way of domain architecture (lytic-CBD-CBD-lytic vs. 
lytic-lytic-CBD), there are virtually no conserved sequences between them, and each utilizes an 
unrelated CBD (Cpl-7-like vs. SH3b).   
 
This pattern is not limited to the streptococcal lysins.  Interestingly, inactive lytic domains are 
also observed in staphylolytic endolysins.  The staphylolytic Ф11 endolysin was shown via 
deletion analysis to have a very active N-terminal D-alanyl-glycyl endopeptidase domain 
(Donovan et al., 2006c;Sass and Bierbaum, 2007) and a nearly silent N-acetylmuramoyl-L-
alanine amidase domain (Sass and Bierbaum, 2007).  The staphylococcal phage endolysin 
LysK shares a high degree of domain architecture with the Ф11 endolysin and shows the same 
pattern of a highly active N-terminal CHAP endopeptidase domain (Becker et al., 2009a;Horgan 
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et al., 2009) and a nearly silent second lytic (amidase) domain.  This pattern also shows up in 
numerous (but not all) SH3b containing staphylococcal endolysins (DMD unpublished data).  
The fact that this pattern is occurring in seemingly unrelated proteins and in more than one 
genera begs the question of why would this be evolutionarily conserved.  A discussion of 
potential explanations has been presented previously (Donovan and Foster-Frey, 2008) and 
thus will not be repeated here, but the most likely explanation lies in the potential (unidentified) 
differences between lysis from without (where these nearly silent domains have been identified) 
vs. lysis from within.  Needed are a series of experiments that test the effect of a mutant 
endolysin gene, with either the active or silent domain ablated, in a wild-type phage lytic cycle. 
 
E.  Measuring endolysin activity  
 
The catabolic activity of PG hydrolases has been studied and quantified for many years.  The 
earliest assays did not focus on antimicrobial activity but rather used PG hydrolase enzymes to 
degrade PG in order to elicit PG structure (Schleifer and Kandler, 1972;Weidel and Pelzer, 
1964).  These early studies laid the ground work for identification of the enzymes as 
antimicrobials.  It should be noted that although multiple assays have been used to quantify the 
PG hydrolase activity, there can be quantitative discrepancies from assay to assay (Kusuma 
and Kokai-Kun, 2005).  Similarly, measuring PG hydrolase enzymatic activity is not the same as 
measuring PG hydrolase antimicrobial activity (which by definition must assay live cells).  
Nonetheless, below is a list of both qualitative and quantitative assays that have been employed 
in the study of PG hydrolases.   
 
Turbidity reduction assays:  A decrease in light scattering (i.e., turbidity reduction) of a 
suspension of live cells, non-viable cells (heat killed or autoclaved), or cell wall 
preparation/extract can be used in a spectrophotometer to assay the activity of PG hydrolases.  
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The reduction in optical density over time (minutes or hours) can be used to calculate a rate of 
hydrolysis (Fig. 6). Results are compared to a “no-enzyme added, buffer only control” 
preparation treated identically for the same period of time.  In this manner, a specific activity of 
the enzyme preparation can be reported as ΔOD/time/µg lysin protein.  Critical to the 
interpretation of these assays include considerations for whether or not: 1) the assay is 
performed in the linear range of enzyme activity with excess substrate always present, 2) the 
maintenance of a homogeneous substrate solution (to avoid the substrate settling out of 
solution), and 3) the requirement for an identically treated no-enzyme control sample, the OD of 
which must be subtracted from the experimental sample result.  There are published results 
using the spectrophotometric turbidity reduction assays to quantify enzyme activity (Filatova et 
al., 2010) and even determine kinetic constants (Mitchell et al., 2010).  However, some caution 
should be used when interpreting the results because a loss of optical density is not always 
directly equated with antimicrobial activity (Fig. 6).  Furthermore, variation in the assay between 
laboratories and arbitrary unit definitions often makes comparison of lytic activities difficult.  
Activities of phage-encoded and bacterial PG hydrolases reportedly range from 102 to 108 
“units” per mg protein (Fukushima et al., 2007;Loeffler et al., 2003;Loessner et al., 
1995a;Nelson et al., 2001;Vasala et al., 1995;Yoong et al., 2006). 
 
Zymogram assay:  Zymograms are a simple way to follow PG hydrolase activity during 
purification.  Briefly, endolysin preparations are electrophoresed in duplicate SDS-PAGE gels.  
The gels are prepared either with or without the target cells or extracted PG embedded in the 
gel during polymerization.   Following electrophoresis, the gel is soaked for 1 hour in a buffer 
compatible with the lytic enzyme to remove the SDS.  The appearance of a cleared region in the 
opaque gel indicates that the cells embedded in the gel were lysed at that location, most likely 
due to a lytic protein/agent in the gel.  This too is not an antimicrobial assay per se as the 
bacterial cells are often heat-treated before mixing them with the gel matrix, and are obviously 
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SDS-treated.  Nonetheless, a zymogram is particularly useful for identifying putative PG 
hydrolases and offers a higher sensitivity level than the turbidity reduction assays.  
 
Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC): MIC 
and MBC are classical assays for quantifying the antimicrobial activity of a variety of drugs.  The 
protocols are described in detail in bacteriological manuals (Jones et al., 1985).  Briefly, a 2X 
dilution series (100, 50, 25 µg, etc.) of the compound to be assayed (i.e. antibiotic or PG 
hydrolase) is established in a defined volume (usually in a 96 well plate) of growth media to 
which a constant number of colony forming units (CFUs) is added (i.e., 1 x 105) and incubated 
overnight at 37ºC.  After 20 hours, the wells are examined for growth or no growth (turbid or 
clear) (Becker et al., 2009a).  The lowest concentration of the compound that can inhibit 
overnight growth is the MIC (usually reported in µg/ml).   For MBC, an aliquot of the wells with 
no apparent growth (clear to the eye) is plated onto agar growth media, and the lowest 
concentration of the compound that results in no CFUs (no viable cells) is the MBC (µg/ml).  All 
PG hydrolase enzymes are not amenable to the MIC assay for reasons unknown.  For these 
enzymes, cleared wells are never obtained, despite highly active PG hydrolase activity in 
multiple other PG hydrolase assays (DMD, unpublished data). 
 
Plate Lysis (spot on lawn): A log growth-phase culture of the target bacteria is plated onto media 
agar plates (e.g. 0.6 ml of culture per 100 mm plate) and allowed to air dry (~15 min.) at room 
temp.  10 µl aliquots of known concentration(s) of the PG hydrolase are spotted onto the lawn 
and allowed to air dry (~10 min.) at room temp.  The plates are incubated at optimal growth 
temperature and the plates assayed after overnight growth.  A cleared spot on an opaque lawn 
indicates lytic antimicrobial activity of the PG hydrolase.  Relative activity levels can be obtained 
by spotting a dilution series on the plate. 
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The disk diffusion assay is a variation of the plate assay, but opposed to spotting a known 
concentration directly onto a recently plated lawn of bacteria, a disk of sterile filter paper with a 
known concentration of PG hydrolase embedded in the disk is placed on the surface of the lawn 
and a ring of growth inhibition or lysis is observed after overnight growth.  This method is not 
only dependent on a lytic agent, but simultaneously requires that the compound does not stick 
to the filter and can diffuse through the agar growth media.  
 
Soft agar overlay assay: For screening of expression libraries for clones producing PG 
hydrolases, a soft agar overlay assay can be performed (Loessner et al., 1995b;Schuch et al., 
2009). Replica plates containing an inducer of protein expression (e.g., IPTG) are created from 
original agar plates containing transformant colonies. The replica plates are incubated at 37°C 
for up to 6 h to allow protein production. Then, the colonies are exposed to saturated chloroform 
vapor for ~5 min in order to disintegrate the cytoplasmic membrane and externalize the 
expressed proteins, and immediately overlaid with soft agar (0.4% agar in water or buffer) 
containing bacterial substrate cells at high concentration. After incubation at room temperature 
(30 min to 18 h), lytic phenotypes can be identified by clear halos in the turbid soft agar layer. 
Subsequently, positive clones can be picked from original plates for plasmid isolation and 
genetic characterization. 
 
 
Interestingly, although each of these assays can quantify the lytic activity of PG hydrolases, 
when a comparison of four different assays (i.e. turbidity, disk diffusion, MIC, and MBC) was 
utilized to quantify the antimicrobial activity of lysostaphin, the results were not always directly 
comparable between assays (Kusuma and Kokai-Kun, 2005).  A similar result indicating 
qualitative but not quantitative agreement between assays was demonstrated with zymogram, 
turbidity reduction, MIC, and plate lysis assays using constructs of LysK, the staphylococcal 
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phage K endolysin (Becker et al., 2009a).   A reasonable explanation for this quandary was 
proposed by Kusuma et al. (Kusuma and Kokai-Kun, 2005) acknowledging that bacteria 
express different surface factors in liquid media than on solid media (culture media can effect 
capsular polysaccharide production in S. aureus).  They also suggest that the MIC assay may 
not be the most appropriate assay for a rapidly acting lytic enzyme, since the MIC assay 
measures growth inhibition while PG hydrolases probably kill the initial inocula rapidly. 
 
F. Cell wall binding domains on Gram-positive endolysins  
 
There are numerous domains that have been assigned CBD status (see Figs. 3, 4 and 5).  Very 
few of these have been demonstrated unequivocally to be true CBDs.  However, their ability to 
confer altered species-/cell wall- specificity is highly suggestive and thus CBD status has been 
assigned.  One of the first PG hydrolase binding domains identified was the Cpl-7 choline 
binding domain of the pneumococcal amidase autolysin, which requires choline or ethanolamine 
to achieve full activation (Garcia et al., 1990).  Significantly, choline moieties are distinctive of 
the pneumococcal cell wall.  When the binding domain of a pneumococcal autolysin (amidase) 
was exchanged with the CBD of the phage lysozyme Cpl-7, a dependence on choline binding 
for enzyme activation was observed (Diaz et al., 1990;Diaz et al., 1991).  Similar Cpl-7-like 
CBDs have been found in a Group B streptococcal λSa2 phage endolysin (Pritchard et al., 
2007) that appear to be essential for lytic activity (Donovan and Foster-Frey, 2008).   
 
Another of the most well studied PG hydrolase CBDs is that of the M23 glycyl-glycine 
endopeptidase, lysostaphin, and it’s homologue ALE-1 that is 80% identical in both the lytic and 
CBDs. The lysostaphin bacterial src homology 3 (SH3b) CBD binds to the pentaglycine 
interpeptide bridge of the S. aureus PG (Grundling and Schneewind, 2006).  The regions and 
exact amino acid residues involved in this binding have been identified in the C-terminal domain 
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via site directed mutagenesis of ALE-1 (Lu et al., 2006).  A recent study reports that both 
lysozyme and lysostaphin are more active when the C-terminus of the Target of RNAIII 
activating protein (TRAP) is present in the staphylococcal cell wall.  Binding studies indicate that 
the binding of these two lytic enzymes to the staphylococcal cell surface is favored by the TRAP 
protein C-terminus (Yang et al., 2008).  Additional (SH3b) domains are found on many phage 
endolysins and appear to bind to the cell wall in an as yet undetermined manner.   
 
For some species, the CBD recognition of an epitope is analogous to recognition of a cell 
surface receptor by a phage tail fiber.  In fact, there is some evidence that these two disparate 
types of proteins have evolved to target identical epitopes.  For example, the γ-phage of Bacillus 
anthracis forms plaques on all tested B. anthracis strains as well as B. cereus 4342, which is 
considered a B. anthracis transition state strain, but not other B. cereus strains (Schuch et al., 
2002).  Significantly, the lytic range of γ-phage endolysin, PlyG, mirrors the host range of the 
phage.  In a similar fashion to pneumococcal phage tail fibers (Lopez et al., 1982), 
pneumococcal lysin CBDs are known to bind choline in the pneumococcal cell wall (Hermoso et 
al., 2003;Lopez et al., 1982;Lopez et al., 1997).  Some CBDs of Listeria phage endolysins are in 
fact not just species-specific, but through binding to presumably teichoic acid moieties achieve 
serovar or even strain specificity (Kretzer et al., 2007;Loessner et al., 2002;Schmelcher et al., 
2010).  However, these highly specific endolysins are exceptions rather than the rule.  In most 
cases, the specificity of the phage is more restrictive than its encoded endolysin.  The C1 
bacteriophage only forms plaques on group C streptococci, yet its endolysin, PlyC, efficiently 
lyses groups A, C, and E streptococci (Krause, 1957), as well as Streptococcus uberis (DCN 
unpublished observation).  An extreme example would be PlyV12, an endolysin derived from 
the enterococcal phage φ1.  This enzyme not only lyses E. faecalis and E. faecium, but it also 
lyses almost all streptococcal strains (groups A, B, C, E, F, G, L, and N streptococci, S. uberis, 
S. gordonii, S. intermedius, and S. parasanguis) as well as staphylococcal strains (S. aureus 
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and S. epidermidus) (Yoong et al., 2004).  Similarly, the Acinetobacter baumannii phage ϕAB2 
endolysin is reported to lyse both Gram-positive and Gram-negative bacteria (Lai et al., 2011).  
 
IV.  Gram-Positive Endolysins as Antimicrobials  
 
A.  In vivo activity  
 
Phage endolysins have been studied extensively for half of a century, particularly those 
endolysins from the T-even phage that infect Gram-negative hosts.  However, it has only been 
in the past ten years that scientists have begun evaluating the use of endolysins, specifically 
endolysins from phage that infect Gram-positive hosts, in animal infection models of human 
disease.  Table 4 shows a complete list to date of all in vivo therapeutic trials that utilize 
bacteriophage-encoded endolysins, which are summarized below.   
 
Fischetti and co-workers were the first to use a purified phage endolysin in an in vivo model 
(Nelson et al., 2001).  It was found that oral administration of an endolysin (250 U) from the 
streptococcal C1 bacteriophage provided protection from colonization in mice challenged with 
107 Streptococcus pyogenes (i.e. group A streptococci) (28.5% infected for endolysin treatment 
vs. 70.5% infected for PBS treatment).  Furthermore, when 500 U of the streptococcal 
endolysin, named PlyC in a later publication (Nelson et al., 2006), was administered orally to 9 
heavily colonized mice, no detectable streptococci were observed 2 hours post-endolysin 
treatment (Nelson et al., 2001).  Based on these results, the authors coined the term 
“enzybiotic” to describe the therapeutic potential of not only the streptococcal endolysin, but all 
bacteriophage-derived endolysins. 
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PlyGBS is another phage endolysin that is active against group A streptococci as well as groups 
B, C, G, and L streptococci (Cheng et al., 2005).  This enzyme was tested in a murine vaginal 
model of Streptococcus agalactiae (i.e. group B Streptococcus) colonization as a potential 
therapeutic for pregnant women to prevent transmission of neonatal meningitis-causing 
streptococci to newborns.  A single vaginal dose of 10 U was shown to decrease colonization of 
group B streptococci by ~3 logs.  Significantly, PlyGBS was found to have a pH optimum ~5.0, 
which is similar to the range normally found within the human vaginal tract.  Moreover, this 
enzyme did not possess bacteriolytic activity against common vaginal microflora such as 
Lactobacillus acidophilus.   
 
The most extensively studied endolysins in animal models are Cpl-1, an N-acetylmuramidase 
from the Cp-1 pneumococcal phage, and PAL, an N-acetylmuramoyl-L-alanine amidase from 
the Dp-1 pneumococcal phage.  100 U/ml of PAL was shown to cause ~4 log drop in viability in 
30 seconds of 15 different Streptococcus pneumoniae serotypes representing multi-drug 
resistant isolates and those that contain a heavy polysaccharide capsule (Loeffler et al., 2001).  
In a mouse model of nasopharyngeal carriage, 1,400 U of PAL was shown to eliminate all 
pneumococci and 700 U was shown to significantly reduce bacterial counts, suggesting a dose 
response.  In another study, Cpl-1 was shown to be effective in both a mucosal colonization 
model and in blood via a pneumococcal bacteremia model (Loeffler et al., 2003).  Because the 
catalytic domains of PAL and Cpl-1 hydrolyze different bonds in the pneumococcal 
peptidoglycan, they were shown to be synergistic when used in combination in vitro (Loeffler 
and Fischetti, 2003) , which was later confirmed in vivo in a murine intraperitoneal infection 
model (Jado et al., 2003).  In a study on the effectiveness of endolysins against in vivo biofilms, 
Cpl-1 was shown to work on established pneumococcal biofilms in a rat endocarditis model 
(Entenza et al., 2005).  Infusion of 250 mg/kg was able to sterilize 105 cfu/ml pneumococci in 
blood within 30 minutes and reduce bacterial titers on heart valve vegetations by >4 log cfu/g in 
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2 hours.  In an infant rat model of pneumococcal meningitis, a single intracisternal injection (20 
mg/kg) of Cpl-1 resulted in a 3 log decrease of pneumococci in the cerebrospinal fluid (CSF) 
and an intraperitoneal injection (200 mg/kg) led to a decrease of 2 orders of magnitude in the 
CSF (Grandgirard et al., 2008).  Finally, because pneumococci are often early colonizers to 
which additional pathogens and viruses adhere, Cpl-1 treatment of mice colonized with S. 
pneumoniae in an otitis media model was shown to significantly reduced co-colonization by 
challenge with influenza virus (McCullers et al., 2007). 
 
Several phage endolysins have also been used against vegetative cells and germinating spores 
of Bacillus species.  50 U of PlyG, an endolysin isolated from the B. anthracis γ phage, was 
shown to rescue 13 out of 19 mice in an intraperitoneal mouse model of infection and extended 
the life of the remaining mice several fold over controls (Schuch et al., 2002).  Significantly, this 
enzyme displayed a favorable thermostability profile and was able to remain fully active after 
heating to 60°C for an hour.  Moreover, the extreme lytic specificity of this enzyme toward B. 
anthracis and not other Bacillus species was exploited for diagnostic purposes in a luminescent-
based ATP assay of B. anthracis cell lysis.  A second Bacillus lysin, PlyPH, is unique in that it 
has a relatively high activity over a broad pH range, from pH 4.0 to 10.5.  This enzyme also 
protected 40% of mice in an intraperitoneal Bacillus infection model compared to 100% death in 
control mice (Yoong et al., 2006).  Taken together, the robust and specific properties of the 
Bacillus endolysins make them amenable to therapeutic treatment and diagnostics of B. 
anthracis. 
 
The prevalence of methicillin-resistant Staphylococcus  aureus (MRSA) as a primary source of 
nosocomial infection and community-acquired MRSA as an emerging public health threat has 
generated a considerable amount of interest in identifying and evaluating highly active 
staphylococcal endolysins.  The first anti-staphylococcal endolysin investigated in vivo was MV-
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L, which was cloned from the ΦMR11 bacteriophage (Rashel et al., 2007).  This enzyme rapidly 
lysed all tested staphylococcal strains, including MRSA and vancomycin-resistant clones.  In 
vivo, 310 U of this enzyme reduced MRSA nasal colonization ~3 logs and 500 U provided 
complete protection in an intraperitoneal model of staphylococcal infection when administered 
30 minutes post-infection.  At 60 minutes post-infection, the same amount of enzyme provided 
protection in 60% of mice vs. controls.  Another staphylococcal endolysin, ClyS, is a chimera 
between the N-terminal catalytic domain of the Twort phage endolysin (Loessner, et al., 1998) 
and the C-terminal cell wall-binding domain of the ΦNM3 phage endolysin (Daniel et al., 2010).  
Like MV-L, this enzyme displayed potent bacteriolytic properties against multi-drug resistant 
staphylococci in vitro.  In a mouse MRSA decolonization model, 2-log reductions in viability 
were observed 1 hour following a single treatment of 960 µg ClyS.  Similarly, a single dose (1 
mg) of ClyS provided protection when administered 3 hours post-staphylococcal challenge in an 
intraperitoneal septicemia model.  Notably, ClyS showed synergy in vivo with oxacillin at doses 
that were not protective individually against a MRSA infection model.  Most recently, 50 µg of an 
endolysin from the GH15 phage, LysGH15, showed 100% protection in a mouse intraperitoneal 
model of septicemia (Gu et al., 2011) and 925 µg of CHAPk, a truncated version of LysK, 
affected a 2 log drop in nasal colonization of mice 1 hour post treatment (Fenton et al., 2010).   
 
In addition to phage-encoded endolysins, a large body of in vivo work devoted to lysostaphin, a 
bacterial-derived exolysin, should not be overlooked.  Lysostaphin, was first identified in 1964 
(Schindler and Schuhardt, 1964) and the  therapeutic potential of this enzyme has been studied 
intensely for almost 50 years.  To name but a few in vivo experiments, this enzyme has been 
investigated in animal models of burn infections (Cui et al., 2011), ocular infections (Dajcs et al., 
2001;Dajcs et al., 2002), systemic infections (Kokai-Kun et al., 2007), keratitis models (Dajcs et 
al., 2000), nasal colonization (Kokai-Kun et al., 2003), and aortic valve endocarditis (Climo et 
al., 1998;Patron et al., 1999).  In addition to human disease, S. aureus is the major cause of 
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acute bovine mastitis in milking cows.  As such, lysostaphin has been evaluated for therapeutic 
use in mouse mammary models (Bramley and Foster, 1990) and bovine mastitis models 
(Oldham and Daley, 1991).  Transgenic mice and cows expressing mammary lysostaphin have 
even been produced and studied for anti-mastitic phenotypes (Kerr et al., 2001;Wall et al., 
2005). 
 
B. Immune responses  
 
Due to the proteinacious nature of PG hydrolases and their potential use as human and animal 
therapeutics, we must consider potential adverse immune responses, including the generation 
of antibodies, to these enzymes.  It is envisioned that PG hydrolases might be applied topically, 
to mucous membranes (oral, nasal, or vaginal cavities), intravenous, or even intramammary in 
the case of bovine mastitis.    
 
To address these questions, serum antibodies were raised to phage endolysins specific to 
Bacillus anthracis, Streptococcus pyogenes, or Streptococcus pneumonia.  When high titers of 
these antibodies were mixed in vitro with the endolysins, killing of the target microbe was 
slowed, but not stopped (Fischetti, 2005;Loeffler et al., 2003).  Cpl-1 is a S. pneumoniae-
specific phage lytic enzyme.  In another study, Cpl-1, a pneumococcal endolysin, was injected 
IV three times per week into mice for four weeks resulting in positive IgG antibodies against Cpl-
1 in 5 of 6 mice.  Vaccinated and naive control mice were then challenged IV with pneumococci 
and the mice were treated IV with 200 µg Cpl-1 after 10 hours.  Bacteremic titers were reduced 
within 1 minute to the same level in both groups of mice (Loeffler et al., 2003).  Furthermore, 
Western blot analysis revealed that both of the phage lytic enzymes Cpl-1 and Pal elicited 
antibodies 10 days after a 200-µg injection in mice, but the second injection (at 20 days) also 
reduced the bacteremia profile 2-3 log units, indicating that the antibodies were not neutralizing 
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in vivo.  All mice recovered fully with no apparent adverse side effects or anaphylaxis noted 
(Jado et al., 2003).  Taken together, these studies suggest that while antibodies can be readily 
raised to endolysins, they do not neutralize their hydrolytic activity in vitro or in vivo.   
 
In recent studies performed with a catheter-induced S. aureus endocarditis model, lysostaphin 
was tolerated following administration by the systemic route with minimal adverse effects (Climo 
et al., 1998).  Rabbits injected weekly with lysostaphin (15 mg/kg) for 9 weeks by the 
intravenous (IV) route produced serum antibodies to lysostaphin that resulted in an eight-fold 
reduction in its lytic activity, consistent with earlier work (Schaffner et al., 1967), but no adverse 
immune response.  It is believed that high purity and the absence of Gram-negative 
lipopolysaccharide are essential for guaranteeing a minimal host immune response.    
 
C. Resistance development  
 
The near-species specificity of phage endolysins avoids many pitfalls associated with broad-
range antimicrobial treatments.  For example, broad-range antimicrobials lead to selection for 
resistant strains, not just in the target pathogen, but also in co-resident commensal bacteria 
exposed to the drug.  The acquisition of antibiotic resistance is often accomplished by transfer 
of DNA sequences from a resistant strain to a susceptible strain.  This transfer is not necessarily 
species or genus limited, and can lead to commensal bacteria that are both antibiotic resistant 
and that can serve as carriers of these DNA elements for propagation to neighboring bacteria.  
Those neighboring strains (i.e., potential pathogens) with newly acquired resistance elements 
can emerge as antibiotic resistant strains during future treatment episodes and be further 
distributed in the bacterial community.  Thus, in order to reduce the spread of antibiotic 
resistance, it is recommended to avoid subjecting commensal bacterial communities to broad-
range antibiotics.   
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To date, there are no reports of strains resistant to phage endolysins.  Two reports have 
attempted to identify resistant strains (summarized in (Fischetti, 2005)).  In brief, three species, 
S. pneumonia, S. pyogenes and B. anthracis, were tested with repeated exposure to sublethal 
doses of phage endolysins specific to each species.  The surviving bacteria were then 
challenged with a lethal dose and there was no notable change in susceptibility.  In another 
study, Bacillus species were exposed to chemical mutagens that increased the frequency of 
antibiotic resistance several orders of magnitude.  In contrast, these organisms remained fully 
sensitive to PlyG, a B. anthracis specific endolysin (Schuch et al., 2002).  A likely explanation 
for the lack of observed resistance in endolysins as put forth by Fischetti is that the bacterial 
host and phage have co-evolved, such that the phage might have evolved endolysins to target 
immutable bonds in order to ensure its survival and release from the host (Fischetti, 2005).  
Thus, resistance to the phage endolysins is expected to be a very rare event. 
 
Despite the lack of observed resistance in the phage endolysins, there are reports of resistance 
to other types of PG hydrolases, specifically exolysins.  Lysozyme is a human exolysin with 
catalytic (muramidase) and cationic antimicrobial peptide activities.  It is secreted by epithelial 
cells, is present on mucous membranes, and in the granules of phagocytes.  Degradation of the 
bacterial peptidoglycan by lysozyme yields peptidoglycan fragments that can elicit a strong host 
immune response and recruitment of immune cells.  Bacterial resistance to lysozyme has been 
accomplished through a variety of modifications that the bacteria can incorporate into the 
peptidoglycan backbone [for recent reviews see (Davis and Weiser, 2011) and (Vollmer, 2008)].   
 
Similarly, there are at least two genes that can confer resistance to the lysostaphin exolysin, 
which targets the bonds of the staphylococcal PG interpeptide bridge.   S. simulans produces 
lysostaphin and avoids its lytic action by the product of the lysostaphin immunity factor (lif) gene 
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[same as endopeptidase resistance gene (epr) (DeHart et al., 1995)] that resides on a native 
plasmid (pACK1) (Thumm and Gotz, 1997). The lif gene product functions by inserting serine 
residues into the PG cross bridge, thus interfering with the ability of the glycyl-glycine 
endopeptidase to recognize and cleave this structure.  Mutations in the S. aureus femA gene 
(factor essential for methicillin resistance) (Sugai et al., 1997) result in a change in the 
muropeptide interpeptide cross bridge from pentaglycine to a single glycine, rendering S. aureus 
resistant to the lytic action of lysostaphin. MRSA have been shown to mutate femA when 
exposed in vitro or in vivo to sub-inhibitory doses of lysostaphin (Climo et al., 2001).  
Interestingly, in one report, MRSA strains that did develop resistance to lysostaphin via the 
femA gene, showed a reduced fitness compared to their parental counter parts, were five-fold 
less virulent in a rodent kidney infection model, and were easily treated with β-lactam antibiotics 
(Kusuma et al., 2007). 
 
Schneewind and colleagues recently identified the  lyrA (lysostaphin resistance A) that, when 
mutated by a transposon insertion, reduced staphylococcal susceptibility to lysostaphin 
(Grundling et al., 2006).  Although some structural changes in PG were noted in the lyrA mutant, 
PG purified from the lyrA mutant was susceptible to lysostaphin and the Ф11 endolysin, 
suggesting that additional unidentified alterations in the S. aureus cell wall envelope might 
mediate resistance in the lyrA mutant. 
 
D. Synergy  
 
Antimicrobial synergy has been demonstrated for multiple PG hydrolases in combination with 
other PG hydrolases as well as numerous other classes of antimicrobials.  Synergy between 
two PG hydrolases was shown with LysK and lysostaphin via the checkerboard assay (Becker 
et al., 2008;Becker et al., 2009a).  This is consistent with the two enzymes having unique cut 
30 
 
sites.  Lysostaphin has also been shown to be synergistic in the checkerboard assay with the 
cationic peptide antimicrobial ranalexin (Graham and Coote, 2007) and this combination  has 
been demonstrated to be an effective surface disinfectant (Desbois et al., 2010).   Lysostaphin 
was also shown to be synergistic with β-lactams against oxicillin-resistant MRSA.  This 
combination is uniquely promising in that lysostaphin resistant staphylococci are generated by 
modifying the pentaglycine bridge of the PG, and these cell wall altered strains are often 
hypersusceptible to β-lactams (Kiri et al., 2002).   The pneumococcal Cpl-1 endolysin is 
synergistic with either penicillin or gentamicin (Djurkovic et al., 2005), and with the Pal amidase 
(Jado et al., 2003;Loeffler and Fischetti, 2003).  The phage endolysin LysH5, which has been 
shown to eradicate S. aureus in milk (Obeso et al., 2008), is synergistic with nisin (Garcia et al., 
2010).  Nisin was also shown to be synergistic with lysozyme against lactic acid bacteria (Chun 
and Hancock, 2000).Finally, ClyS, a fusion lysin described above, has been shown to be better 
than mupirocin at eradicating staphylococcal skin infections (Pastagia et al., 2011) and is 
synergistic with oxacillin (Daniel et al., 2010). 
 
E. Biofilms  
 
A high level of antimicrobial resistance is achieved by many pathogens through the multi-
faceted changes that accompany growth in a biofilm.  Biofilms are sessile forms of bacterial 
colonies that attach to a mechanical or prosthetic device or a layer of mammalian cells and has 
an extensive extracellular matrix. NIH estimates that 80% of human bacterial infections involve 
biofilms (http://grants.nih.gov/grants/guide/pa-files/PA-06-537.html) (Sawhney and Berry, 2009).  
Bacteria in biofilms can be orders of magnitude more resistant to antibiotic treatment than their 
planktonic (liquid culture) counterparts (Amorena et al., 1999).   
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Several mechanisms are thought to contribute to the antimicrobial resistance associated with 
biofilms: 1) delayed or restricted penetration of antimicrobial agents through the biofilm 
exopolysaccharide matrix; 2) decreased metabolism and growth rate of biofilm organisms which 
resist killing by compounds that only attack actively growing cells; 3) increased accumulation of 
antimicrobial-degrading enzymes; 4) enhanced exchange rates of drug resistance genes; and 5) 
increased antibiotic tolerance (as opposed to resistance) through expression of stress response 
genes, phase variation, and biofilm specific phenotype development (Emori and Gaynes, 
1993;Fux et al., 2003;Keren et al., 2004;Lewis, 2001).  
 
Little work has been done to specifically test phage endolysins for their anti-biofilm activity. Ф11 
endolysin (Sass and Bierbaum, 2007) and lysostaphin have been shown to eliminate static 
staphylococcal biofilms (Walencka et al., 2005;Wu et al., 2003), as has  LysK (O'Flaherty et al., 
2005).  Lysostaphin was also shown to eliminate staphylococcal biofilms in jugular vein 
catheterized mice (Kokai-Kun et al., 2009).   Recently, the S. aureus SAP-2 phage endolysin 
SAL-2, which is nearly identical to the phage P68 endolysin, was also reported to eliminate S. 
aureus biofilms (Son et al., 2010). Alternative strategies for eradicating biofilms are necessary, 
including catalytic enzymes to destroy the matrix.  Bacteriophage and phage lytic enzymes are 
a potential new source of anti-biofilm therapy (Donlan, 2008),   
 
F. Disinfectant use  
 
Decontamination of environmental pathogens is another area where PG hydrolases may find a 
niche in the marketplace.  Although most disinfectants have broad-spectrum efficacy, one can 
envision environments where targeted decontamination of a pathogen by a narrow-spectrum 
endolysin would be sufficient.  For example, endolysins targeting MRSA may have utility in 
nursing homes, surgical suites, or athletic locker rooms; endolyins effective against Bacillus 
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anthracis may be important for decontamination of suspected exposures; those against Listeria 
monocytogenes would have applications in meat-packing or food-processing facilities; and 
enzymes against group A streptococci could be used to reduce bacterial loads in child care 
settings.      
 
Endolysins avoid several problems that are associated with chemical disinfectants.  By their 
enzymatic nature, endolysins do not rely on potentially toxic reactive groups utilized by chemical 
disinfectants.  As proteins, they are inherently biodegradable and non-corrosive (i.e. a “green” 
disinfectant).  Finally, due to the high affinity of their binding domains for the bacterial 
peptidoglycan and their ability to concentrate on the cell surface, endolyins may not be as 
susceptible to dilution factors as are chemical disinfectants. 
 
To date, the literature is sparse with examples of PG hydrolases used for disinfecting purposes.  
Nonetheless, lysostaphin and the cationic peptide antimicrobial ranalexin have been shown to 
be synergistic at killing MRSA on solid surfaces (Graham and Coote, 2007).  Similarly, the same 
combination was found to kill MRSA on human skin within 5 minutes using an ex vivo assay 
(Desbois et al., 2010).  In one unique application, lysostaphin attached to nanotubes and mixed 
with latex paint was shown to retain anti-staphylococcal properties on painted surfaces (Pangule 
et al., 2010)   
 
For endolysins, only PlyC has been tested specifically as an environmental disinfectant (Hoopes 
et al., 2009).  PlyC lyses several streptococcal species including S. equi, the causative 
organism of equine strangles disease.  This highly contagious disease of horses is transmitted 
through shedding of live bacteria from nasal secretions and abscess drainage onto common 
surfaces in a stall or barn.  Chemical disinfectants can be effective against S. equi, but 
inactivation by environmental factors, damage to equipment, and toxicity are of concern.  PlyC 
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was found to be 1,000 times more active on a per weight basis (~150,000 times more active on 
a molar basis) than a commercially available oxidizing disinfectant.  Significantly, 1 µg of PlyC 
was able to sterilize 108 cfu/ml of S. equi in 30 minutes.  Based on these findings, the authors 
performed a standard battery of tests approved by the Association of Official Analytical 
Chemists (AOAC), including the Use Dilution Method for Testing Disinfectants and the 
Germicidal Spray Products Tests.  PlyC passed the Use Dilution Method, which validates 
disinfectant claims, and was shown to eradicate or significantly reduce the S. equi load on 
equipment of various porosities commonly found in horse stables.  Finally, PlyC was shown to 
retain effectiveness when tested in the presence of non-ionic detergents, hard water, and 
organic material. 
 
G. Food safety  
 
The use of phage and phage products for use in food safety has been reviewed recently 
(Hagens and Loessner, 2010;Hermoso et al., 2007;O'Flaherty et al., 2009).  ListShield™ and 
Ecoshield™ from Intralytix and LISTEXTM from EBI Food Safety are phage preparations 
designed to protect food from Listeria monocytogenes or E. coli.  One regulatory distinction 
between phage and endolysins is that phage are considered a natural product and most 
endolysins are purified from a recombinant expression system, thus increasing the hurdles in 
the approval process.   
 
The specific use of PG hydrolases to protect food from bacterial pathogens has also been 
reviewed recently (Callewaert et al., 2010;Garcia et al., 2011;Loessner, 2005;Stark et al., 2010).  
Despite extensive exploration in this area, at this writing, there are no approved enzybiotics 
(endolysins) for use in/on foods for human consumption. However, approval is anticipated 
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eventually, in light of the acceptance in 2006 by the US, FDA for the use of Listeria 
bacteriophage on sliced meat products. 
 
PG hydrolases are effective antimicrobials when introduced into food stuffs via transgene 
expression, but the safety of consumption of transgenic food products is still a highly debated 
topic worldwide.  Transgenic goat milk containing human lysozyme could protect from mastitis in 
vitro and showed benefits in animal health for goats drinking the transgenic milk (Maga et al., 
2006b;Maga et al., 2006a).  Similarly, pigs (Tong et al., 2010) and cattle (Yang et al., 2011) 
expressing lysozyme in the mammary gland have been created.  Lysostaphin transgenic cattle 
were also protected from an intramammary S. aureus challenge (Wall et al., 2005).  A human 
lysozyme expressing vector for injection into cattle mammary glands has also been created and 
reported to reduce mastitis symptoms within days (Sun et al., 2006).   
 
Expression of PG hydrolases in plants might serve multiple purposes: first, as a final stage to 
protect food products from food pathogens or a method to protect crop production from plant 
pests and finally, plant systems might be a better source of the PG hydrolase in quantities 
needed for commercialization as opposed to fermentation-derived recombinant proteins.  
Potatoes can be protected from the phytopathogen Erwinia amylovora by the transgenic 
expression of the T4 lysozyme (During et al., 1993).  Transgenic rice expressing human 
lysozyme has also been created (reviewed in (Boothe et al., 2010)) as have transgenic plants 
expressing a group B streptococcal endolysin, which was highly expressed in the chloroplasts 
(Oey et al., 2009).   
 
Non-transgenic uses of PG hydrolases in food applications are limited.   Surface application of 
the phiEa1h (T4 lysozyme) endolysin on pears reduced the effects of an Erwinia challenge (Kim 
et al., 2004).  The staphylococcal phage endolysin LysH5 killed S. aureus in pasteurized milk in 
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vitro (Obeso et al., 2008) and was recently shown to be synergistic with nisin, a lactococcal 
bacteriocin that has achieved GRAS status (generally recognized as safe) (Garcia et al., 2010).  
A fusion of a streptococcal B30 endolysin and lysostaphin was also able to kill both streptococci 
and staphylococci in milk products (Donovan et al., 2006a).  An endolysin from Clostridium 
tyrobutyricum (Mayer et al., 2010), which produces cheese spoilage, is also active in milk. Other 
clostridial endolysins that kill food pathogens have been reported (Zimmer et al., 2002;Simmons 
et al., 2010). Lactic acid bacteria engineered to secrete lysostaphin and a Listeria endolysin 
(Tan et al., 2008;Turner et al., 2007) or Listeria endolysin alone (Gaeng et al., 2000;Stentz et 
al., 2010) or Clostridium endolysin (Mayer et al., 2008) have been produced, but the ability to 
protect food stuffs from these pathogens has not yet been reported. 
 
A very relevant role that endolysins play in food safety is based on the high specificity of their 
CBDs. These recognition domains have been used to develop rapid and sensitive identification, 
detection and differentiation systems (Fujinami et al., 2007;Schmelcher et al., 2010). Magnetic 
beads coated with recombinant CBDs enabled immobilization and recovery of more than 90% of 
L. monocytogenes cells from food samples (Kretzer et al., 2007;Walcher et al., 2010). 
 
V.  Engineering Endolysins   
  
A.  Swapping and/or combining endolysin domains  
 
There are numerous examples in the literature of engineered PG hydrolases that range from 
site-directed mutant constructs used to identify essential amino acids in catalytic or CBD 
domains, to novel fusion constructs for the purpose of making a better antimicrobial.  Some of 
the earliest fusions were created by the exchange of CBDs of pneumococcal autolysins and 
phage endolysins (Diaz et al., 1991;Garcia et al., 1990). Fusion of clostridial or lactococcal N-
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acetylmuramidase catalytic domains to choline binding domains from pneumococcal endolysin 
CBDs resulted in choline dependence of the chimeric enzyme (Croux et al., 1993a;Croux et al., 
1993b;Lopez et al., 1997).  In a reverse approach, a clostridial CBD was fused C-terminally to a 
catalytic domain of the pneumococcal autolysin LytA, considerably increasing its activity against 
clostridial cell walls (Croux et al., 1993a).  In another study, the catalytic domain of the 
lactococcal phage Tuc2009 gained activity against choline-containing pneumococcal cell walls 
by fusion to the CBD of LytA (Sheehan et al., 1996).  The ability to swap catalytic and CBDs is 
not limited to choline-binding domains.  The exchange of Listeria phage endolysin CBDs of 
different serovar specificity resulted in swapped lytic properties of the chimeras and enhanced 
lytic activity against certain strains (Schmelcher et al., 2011).  In the same study, heterologous 
tandem CBD constructs were shown to combine the binding properties of both individual CBDs, 
providing them with extended recognition properties. Furthermore, a duplication of a CBD 
resulted in a 50-fold increase in affinity to the listerial cell wall, making this protein a useful tool 
for bacterial detection. Combined with an enzymatically active catalytic domain, this increased 
affinity resulted in enhanced lytic activity at high ionic strength.  Another chimeric endolysin 
(P16-17) was recently constructed with the N-terminal predicted d-alanyl-glycyl endopeptidase 
domain and the C-terminal CBD of the S. aureus phage P16 endolysin and the P17 minor coat 
protein, respectively. This approach was also a domain-swap which greatly improved the 
solubility of the fusion over the parental hydrolases, allowing purification and experiments to 
demonstrate strong antimicrobial activity towards S. aureus (Manoharadas et al., 2009).   
 
A series of intergeneric PG hydrolase fusions between the streptococcal B30 endolysin and the 
staphylolytic lysostaphin demonstrate activity against both pathogens (Donovan et al., 2006a).  
These constructs relied on the streptococcal and staphylococcal lytic domains maintaining their 
parental specificities, with just the lysostaphin SH3b CBD.  This dual lytic specificity challenges 
the dogma wherein the SH3b domain was believed to be essential for endolysin specificity 
37 
 
(Baba and Schneewind, 1996).   More recently, this theme has been expanded to include the 
streptococcal phage λSa2 endolysin CHAP endopeptidase domain fused to the ~92 amino acid 
staphylococcal SH3b CBDs from either lysostaphin or LysK.  These constructs show full activity 
against both streptococcal and staphylococcal pathogens in numerous in vitro assays (Becker 
et al., 2009b), presumably due to the conserved bonds that this lytic domain recognizes and 
cleaves (γ-D-glutaminyl-L-lysine) in both streptococcal and staphylococcal PG.   Again, the 
staphylococcal SH3b CBDs enhanced lytic activity on cell walls of both genera.  This dual 
activity argues against genera- or species-specific binding of the lysostaphin SH3b domain as 
has been reported (Grundling and Schneewind, 2006;Lu et al., 2006).   
 
A more recent fusion, ClyS, described above  is reported to be effective at curing murine topical 
infections of S. aureus (Pastagia et al., 2011) and effective in combination with classical 
antibiotics at eradicating multi-drug resistant strains of S. aureus in  a mouse model of nasal 
colonization (Daniel et al., 2010). 
 
Other more trivial modifications of PG hydrolases have also been reported, such as the addition 
of a His-tag for ease of purification.  Although such tags are considered a minor modification, 
rarely has the effect of such a modification been examined on lytic activity. One recent study 
has examined the effect of an N- or C-terminal His tag on lysostaphin with the resultant activities 
being 80% and 20% of the non-tagged version, respectively (Becker et al., 2011).  That same 
publication also looked at micro deletions (6 amino acid increments) in the N-terminus of 
lysostaphin.  Deletion of the first 3 or 6 residues has no significant effect on minimum inhibitory 
concentration (MIC), whereas deletion to residue 11 reduces the MIC to ~40% of wild-type with 
decreasing MICs for larger deletions.  The lack of reproducibility of quantitative results between 
PG hydrolase assays for lysostaphin was first described by Kusuma et al, (Kusuma and Kokai-
Kun, 2005) and that finding was confirmed recently with turbidity reduction and plate lysis 
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assays where N-terminal micro-deletions of lysostaphin did not show significant reduction in lytic 
activity until 21 residues were deleted resulting in only 17% of wild-type activity (Becker et al., 
2011).   
 
Other minimally altered constructs are those where single amino acids are purposefully altered 
to examine the effect on lytic activity.  Pritchard and colleagues altered conserved amino acids 
in the streptococcal B30 endolysin CHAP and lysozyme domains, which resulted in sequential 
loss of activity from each domain.  When analyzed on live bacteria, it was made clear that the 
B30 endolysin CHAP domain was the primary source of lytic activity from this dual domain 
endolysin when lysing ‘from without’ (Donovan et al., 2006b).  Site-directed mutagenesis and 
deletion analysis of the Bacillus anthracis phage lysin PlyG were essential in defining the 
binding domain and active site residues (Kikkawa et al., 2007;Kikkawa et al., 2008), as for  PlyC 
that was also examined in this way (Nelson et al., 2006).  Similarly, site-directed mutations 
altering histidine codons in the staphylococcal glycyl-glycine PG hydrolase ALE-1 have been 
used to define essential amino acids in the M23 endopeptidase domain (Fujiwara et al., 2005).  
Mutations of the ALE-1 CBD when fused to GFP were used to define those amino acids 
essential for cell wall binding (Lu et al., 2006).   
 
Further site-directed mutations of lysostaphin were examined when a lysostaphin transgene 
was expressed in the mammary gland of both mice (Kerr et al., 2001) and dairy cattle (Wall et 
al., 2005).  Transgenic lysostaphin showed reduced activity due to N-linked glycosylation (Kerr 
et al., 2001).  Subsequently, two Asn codons (residues 125 and 232) were modified to encode 
Glu in order to ablate the N-linked glycosylation.  The result was a secreted functional 
lysostaphin, however, with a 5-10 fold reduction in lytic activity compared to wild-type 
lysostaphin (Kerr et al., 2001).   It was recently shown by separating the two altered residues on 
separate constructs, that the N125Q modification alone was primarily responsible for this 
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reduction in activity (Becker et al., 2011).  By homology to the well characterized LytM (a closely 
related LAS metalloprotease) (Firczuk et al., 2005), residue 125 is likely to reside in the catalytic 
domain of lysostaphin, and thus may alter the enzymes ability to bind the substrate.  When 
mapped to the crystal structure of LytM  (Firczuk et al., 2005) in the presence of a substrate 
analogue bound to a glycine rich loop  in the active site cleft, mutation of the equivalent residue 
(LytM N303Q) added an additional carbon into the side chain in the predicted active site.  It is 
predicted that this might crowd the substrate analog and therefore interfere with substrate 
binding in the active site cleft (Firczuk et al., 2005; Becker et al., 2011). 
 
Numerous engineered truncations of PG hydrolases have been described in the literature that 
were created primarily for defining active residues in lytic domains.   A partial list includes the 
Twort endolysin (Loessner et al., 1998), B30 endolysin (Donovan et al., 2006b), λSa2 endolysin 
(Donovan and Foster-Frey, 2008), Ф11 endolysin (Donovan et al., 2006c;Sass and Bierbaum, 
2007), and the Bacillus amyloliquifaciens endolysin (Morita et al., 2001).  Some of these efforts 
have yielded truncations with a greater lytic specific activity than the full length PG hydrolase 
e.g. the staphylococcal LysK (Horgan et al., 2009).  One such hyper-active truncation construct 
was the result of a random mutagenesis experiment which also resulted in the incorporation of 
unpredicted sequences at the C-terminus of the streptococcal PlyGBS endolysin (Cheng and 
Fischetti, 2007).  The authors suggest this enhanced activity may be potentially due to both a 
reduced size and the lack of full-length CBD, allowing the enzyme to move more quickly 
between substrate binding sites and thus lyse more cells. Other studies suggest that the 
presence of a CBD increases lytic activity of an endolysin, presumably by bringing the catalytic 
domain in proximity of its substrate (Korndorfer et al., 2006). However, duplication of a CBD, 
which results in a significant increase in binding affinity, was shown to reduce activity at 
physiological salt concentration, which again may be explained by a loss of surface mobility 
(Schmelcher et al., 2011). 
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The numerous works with fusion constructs further verify that PG hydrolases have evolved a 
modular design, with both lytic and CBD domains as first proposed by Diaz et al. (Diaz et al., 
1990).  When fused, these lytic domains can maintain their parental specificities for the PG 
bond cleaved, and the species of cell wall recognized.  These enzymes are candidate 
antimicrobials for the reasons outline above, but most importantly, despite repeated attempts to 
identify them, no strains of host bacteria have been reported that can resist the lytic activities of 
their bacteriophage endolysins (Fischetti, 2005).  In addition, numerous phage endolysins 
harbor dual lytic domains (See Figs. 3, 4 and 5).  Dual domain endolysins are predicted to be 
more refractory to resistant strain development (Fischetti, 2005).  The Donovan lab has taken 
this one step further and reasoned that three lytic domains might create an antimicrobial that 
would be even more refractory to resistance development.  In theory, it is very rare that a 
bacterium can evade three, unique, simultaneous antimicrobial activities.   
 
We have created several triple-lytic-domain anti-staphylococcal fusion constructs using the 
synergistic enzymes LysK and lysostaphin.  Lysostaphin and LysK collectively harbor three 
unique cleavage sites that are known (described above).  LysK and lysostaphin are also known 
to be active against multiple MRSA strains.  The LysK-Lyso triple lytic domain construct 
described previously (Becker et al., 2009b) is highly active against both S. aureus, MRSA and 
numerous coagulase negative staphylococci (unpublished data).  Most importantly, all three lytic 
domains are active in the fusion construct, as demonstrated by electron spray ionization mass 
spectrometry of PG digestion products (Donovan et al., 2009).   Studies are underway to 
determine the efficacy of these and other triple-lytic-domain fusion endolysins in animal models 
of staphylococcal infection, and to test for resistant strain development both in vitro and among 
the staphylococci retrieved from in vivo models.  
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B.  Fusion of endolysins to protein transduction domains 
 
It is apparent that the high antimicrobial resistance of some persistent pathogens is due to their 
ability to invade and reside intracellularly within eukaryotic cells.  Some examples of bacteria 
that utilize this niche are Legionella pneumophila, Mycobacteria turberculosis, Listeria 
monocytogenes (Vazquez-Boland et al., 2001) and S. aureus.  There are numerous strategies 
that these intracellular residents have devised, including the creation of specialized vacuoles 
that block phagosome maturation into a phagolysosome and inhibition of phagosome 
acidification, to name a few (Garcia-del and Finlay, 1995).  Recent works describe alternative 
drug treatment systems for delivery of antimicrobials to intracellular pathogens (Imbuluzqueta et 
al., 2010).    
 
One recently proposed method involves fusing cell-penetrating peptides (CPPs) or protein 
transduction domains (PTDs) to PG hydrolases to enable these lytic enzymes access to 
intracellular bacteria (Borysowski and Gorski, 2010).  CPPs or PTDs are usually highly 
positively charged regions that exist in naturally occurring proteins and are essential for the 
uptake of these proteins into target cells.  The uptake mechanisms are likely cell type and 
peptide specific with some CPPs and their cargo traversing the membrane without involving 
pinocytosis while others require pinocytotic  uptake  (Duchardt et al., 2007;Joliot and Prochiantz, 
2004).   There are reports of non-charged peptide fragments that can also enhance transduction 
across the eukaryotic membrane, and some antimicrobial peptides can serve as CPPs and vice 
versa (Splith and Neundorf, 2011). 
 
There are numerous reports on the use of CPPs to deliver bioactive molecules to a variety of 
cell types.  Although no formal report exists in the literature for a PG hydrolase fused to a PTD 
for killing intracellular pathogens, there has been one patent application filed in 2009 wherein 
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lysostaphin was fused to the HIV Transactivator of transcription (TAT) protein transduction 
domain, Lyso-TAT (http://www.pat2pdf.org/patents/pat20110027249.pdf).  In this application, 
the Lyso-TAT construct is reported to eradicate S. aureus ex vivo in cultured MAC-T mammary 
epithelial cells, bovine brain epithelia, human keratinocytes and murine osteoblasts.   
 
VI.  Gram-Negative Endolysins as Antimicrobials  
 
A.  Background  
 
The use of bacteriophage-encoded endolysins, or any type of PG hydrolase, to control Gram-
negative pathogens has been very limited.  Their effectiveness when added exogenously is 
hindered by the presence of the Gram-negative outer membrane that is highly effective at 
excluding large molecules and not present on Gram-positive cells.  The endolysin-susceptible 
PG layer resides between an inner and outer membrane in Gram-negative organisms, and as 
such, is not directly exposed to the extracellular environment.  An effective strategy to allow 
endolysins to translocate the outer membrane is vital for their use against Gram-negative 
pathogens.   
 
There are numerous studies on the use of peptides, detergents, and chelators that can be used 
to permeabilize the Gram-negative outer membrane in combination with PG hydrolases (Vaara, 
1992).  As an example, 10 mM EDTA used in combination with 50µg/ml of the Pseudomonas 
endolysin EL188 decreased viable P. aeruginosa cells by 3 or 4 logs in 30 minutes depending 
on the strain tested (Briers et al., 2011).  Additionally, there have been studies in which various 
chemical moieties have been conjugated to PG hydrolases or hydrophobic peptides have been 
genetically fused to them in order to alter membrane permeability to these enzymes (Ito et al., 
1997;Masschalck and Michiels, 2003).  All of these strategies can be applied to bacteriophage-
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derived endolysins and several specific examples are provided in the next section.  However, 
each strategy also poses questions regarding their efficacy, practicality, and toxicity that must 
be determined empirically.  Appreciably, agents that destabilize the Gram-negative outer 
membrane often destabilize eukaryotic cell membranes, both of which are similar lipid bilayers. 
 
B.  Non-enzymatic domains and recent successes  
 
Some PG hydrolases and endolysins can kill pathogens via a mechanism completely separate 
from their ability to enzymatically cleave the PG.  For example,  heat-denatured bacteriophage 
T4 lysozyme was found to retain 50% of its microbicidal activity despite a complete absence of 
muramidase activity (During et al., 1993).  The authors further identified three positively 
charged, amphipathic helices and show that one of them, A4, exhibits 2.5 times more killing of 
E. coli than intact T4 lysozyme.  A4 is proposed to act by membrane disruption due to its 
cationic nature.  This action may be similar to that of other positively charged, amphipathic 
helices collectively referred to as host-defense peptides (Sahl and Bierbaum, 2008).    
 
Similar to the T4 lysozyme, several additional endolysins have been identified which contain 
amphipathic or highly cationic regions in addition to their catalytic domains.  The preliminary 
studies suggest these endolysins are capable of producing lysis from without in a variety of 
Gram-positive and Gram-negative species.  For example, LysAB2, the endolysin from the ΦAB2 
A. baumanni phage, was found to degrade isolated cell walls of A. baumanni and S. aureus in a 
zymogram (Lai et al., 2011).  On live, viable cells, this enzyme was shown to be antibacterial 
toward several Gram-negative (A. baumanni, E. coli, Salmonella enterica) and Gram-positive 
(Streptococcus sanguis, S. aureus, Bacillus subtilis) strains.  Significantly, LysAB2 contains a C-
terminal amphipathic region that was shown by deletion analysis to be necessary for the 
observed antibacterial activity.  A second example is the lys1521 endolysin from a Bacillus 
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amyloliquefaciens phage, which possesses two cationic C-terminal regions.  Using either a 
synthesized peptides of these regions or a catalytically inactive mutant of the endolysin, the 
cationic regions alone were shown to be able to permeabilize the outer membrane of P. 
aeruginosa, a Gram-negative pathogen (Muyombwe et al., 1999).  The wild-type enzyme, 
containing an N-terminal catalytic domain and the two C-terminal cationic domains, displayed 
antibacterial activity against live P. aeruginosa (Orito et al., 2004). 
 
These recent successes have inspired renewed interest in the use of endolysins against Gram-
negative bacteria, an idea once considered a non-starter.  Indeed, several new patents have 
been issued, which provide forward-looking insight into where the field is headed (see patents 
WO/2010/149792 and WO/2011/023702).  It is expected that research focused on fusing 
endolysin catalytic domains with cationic peptides, polycationic peptides, amphipathic peptides, 
sushi peptides, hydrophobic peptides, defensins, and other antimicrobial peptides in the hopes 
of expanding endolysin-based therapy to Gram-negative pathogens will greatly expand in the 
coming years.   
 
C.  High-pressure treatment  
 
In another approach, the use of high hydrostatic pressure (HHP) can dramatically increase 
access of phage endolysins to the Gram-negative PG.  While this may not have direct human 
applications, it does have potential applications for decontamination and food processing.  HHP 
has several advantages: it can be bactericidal alone (Briers et al., 2008;Hauben et al., 
1996;Masschalck et al., 2000;Masschalck et al., 2001;Nakimbugwe et al., 2006), it does not use 
heat so it will not compromise the quality of foodstuffs, and most importantly, it is not considered 
to be a food additive.  However, generating the required high pressures (200 to 500 MPa) can 
pose a cost hurdle.  HHP has been used with a variety of antibacterials including nisin, 
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lactoferrin, and several PG (Briers et al., 2008;Hauben et al., 1996;Masschalck et al., 
2000;Masschalck et al., 2001;Nakimbugwe et al., 2006).   
 
Nakimbugwe and colleagues tested HHP in conjunction with six individual PG hydrolases, 
including phage endolysins from λ and T4, on ten different bacterial strains (five each of Gram-
negative and -positive) (Nakimbugwe et al., 2006). Both phage endolysins were active on four 
out of five of the Gram-negative bacteria and Bacillus subtilis, though the λ-derived endolysin 
showed greater activity on most of the strains.  In a separate study, the efficacy of hen egg 
white lysozyme, a PG hydrolase, and the λ lysozyme, an endolysin, were tested in conjunction 
with HHP on skim milk (pH 6.8) and banana juice (pH 3.8) with four Gram-negative bacteria: E. 
coli O157:H7, Shigella flexneri, Yersinia enterocolitica, and Salmonella typhimurium 
(Nakimbugwe et al., 2006).  The λ lysozyme outperformed the PG hydrolase in a bacterial 
inactivation assay by almost 2 and 5 logs in skim milk and banana juice, respectively.   
 
VII.  Concluding Remarks   
 
Multi-drug resistant super-bugs have ‘raised the bar’ establishing a higher set of requirements 
for new antimicrobials.  New antimicrobial agents should ideally eradicate multi-drug resistant 
pathogens, including those in biofilms, and successfully prevent further resistance development.  
PG hydrolases and their fusions have unique properties that make them ideal candidates for 
this much needed new class of therapeutics.  PG hydrolases usually target a narrow range of 
closely related pathogens, avoiding selective pressures on un-related commensal bacteria.   
They also target the cell surface and thus avoid the many resistance mechanisms that operate 
within the cell (e.g. modification of target, modification of agent, pumps to extrude the agent).  
PG hydrolases are effective against growing cells but can also target non-dividing or slowly 
growing cells e.g. biofilms, which most antibiotics cannot.  The modular nature of the phage 
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endolysins and other PG hydrolases allow for naturally occurring and engineered lysins with two 
or more simultaneous lytic activities.  It is expected to be a rare event that any pathogen can 
evade three simultaneous lytic activities.  It is also worth noting that the ability to confer 
intracellular killing via PG hydrolase fusions to protein transduction domains is non-trivial in light 
of the toxic levels required for most drugs to eradicate pathogens residing intracellularly.  
Similarly, the PG hydrolases are synergistic with many classes of classical antimicrobials, thus 
potentially extending the clinical half-life of over-used antibiotics.  Although there are many 
advantages conferred by killing a drug-resistant pathogen via a lytic enzyme that lyses from 
without, the reality of increased antigen release that accompanies lysis of a systemic pathogen 
cannot be ignored. Similarly, the inherent hurdles of production costs and antigenicity of a 
protein antimicrobial are still awaiting full debate in the commercialization arena.  However, 
despite these concerns, it is clear that biofilms are the major threat in human infectious disease 
with NIH estimating 80% and CDC estimating 65% of human infections are in the form of 
biofilms.  It is also clear that conventional antimicrobials are poor eradicators of biofilms, and 
that catalytic enzymes of some sort are going to be required to dissolve and eradicate persistent 
biofilms.  Thus, the antigenicity of both the digestive enzyme used to treat the biofilm, and the 
surge of  bacterial antigens released upon cell lysis or biofilm degradation are hurdles that will 
need to be overcome in the unavoidable assault on bacterial biofilms.  We believe that PG 
hydrolases are an ideal candidate class of novel antimicrobials with which to address these 
inevitable concerns. 
 
 
Acknowledgements:   
The U.S. Department of Agriculture (USDA) prohibits discrimination in all its programs and 
activities on the basis of race, color, national origin, age, disability, and where applicable, sex, 
marital status, familial status, parental status, religion, sexual orientation, genetic information, 
47 
 
political beliefs, reprisal, or because all or part of an individual's income is derived from any 
public assistance program. (Not all prohibited bases apply to all programs.) Persons with 
disabilities who require alternative means for communication of program information (Braille, 
large print, audiotape, etc.) should contact USDA's TARGET Center at (202) 720-2600 (voice 
and TDD). To file a complaint of discrimination, write to USDA, Director, Office of Civil Rights, 
1400 Independence Avenue, S.W., Washington, D.C. 20250-9410, or call (800) 795-3272 
(voice) or (202) 720-6382 (TDD). USDA is an equal opportunity provider and employer.  This 
work was supported in part by NIH grant1RO1AI075077-01A1; NRI grant 2007-35204-18395 
and US State Dept funds, all awards to DMD. Mention of trade names or commercial products 
in this article is solely for the purpose of providing specific information and does not imply 
recommendation or endorsement by the U.S. Department of Agriculture.   
Jochen Klumpp was funded via a fellowship under the OECD Co-operative Research Program: 
Biological Resource Management for Sustainable Agricultural Systems.  
 
 
 
 
Amorena, B., Gracia, E., Monzon, M., Leiva, J., Oteiza, C., Perez, M., Alabart, J. L. and 
Hernandez-Yago, J. (1999). Antibiotic susceptibility assay for Staphylococcus aureus in biofilms 
developed in vitro. J. Antimicrob. Chemother. 44: 43-55. 
Anantharaman, V. and Aravind, L. (2003). Evolutionary history, structural features and 
biochemical diversity of the NlpC/P60 superfamily of enzymes. Genome Biol. 4: R11. 
Baba,T. and Schneewind, O. (1996). Target cell specificity of a bacteriocin molecule: a C-
terminal signal directs lysostaphin to the cell wall of Staphylococcus aureus. EMBO J. 15: 4789-
4797. 
Baker, J.R., Liu, C., Dong, S., and Pritchard, D.G. (2006). Endopeptidase and glycosidase 
activities of the bacteriophage B30 lysin. Appl. Environ. Microbiol. 72: 6825-6828. 
Bateman, A., and Rawlings, N. D. (2003). The CHAP domain: a large family of amidases 
including GSP amidase and peptidoglycan hydrolases. Trends Biochem. Sci. 28: 234-237. 
48 
 
Bateman, A. and Bycroft, M. (2000). The structure of a LysM domain from E. coli membrane-
bound lytic murein transglycosylase D (MltD). J. Mol. Biol. 299: 1113-1119. 
Becker, S.C., Foster-Frey, J. and Donovan, D. M. (2008). The phage K lytic enzyme LysK and 
lysostaphin act synergistically to kill MRSA. FEMS Microbiol Lett. 287: 185-191.  
Becker, S.C., Dong, S., Baker, J. R., Foster-Frey, J., Pritchard, D. G., and Donovan, D. M. 
(2009a). LysK CHAP endopeptidase domain is required for lysis of live staphylococcal cells. 
FEMS Microbiol. Lett. 294: 52-60. 
Becker, S.C., Foster-Frey, J., Stodola, A. J., Anacker, D. and Donovan, D. M. (2009b). 
Differentially conserved staphylococcal SH3b_5 cell wall binding domains confer increased 
staphylolytic and streptolytic activity to a streptococcal prophage endolysin domain. Gene. 443: 
32-41. 
Becker, S.C., Foster-Frey, J., Powell, A., Kerr, D. and Donovan, D. M. (2011). Lysostaphin: 
molecular changes that preserve staphylolytic activity. In 2010 International Conference on 
Antimicrobial Research, (ed. A.Mendez-Vilas), pp. 18-22. World Scientific Publishing Co., 
Singapore. 
Boothe, J., Nykiforuk, C., Shen, Y., Zaplachinski, S., Szarka, S., Kuhlman, P., Murray, E., 
Morck, D., and Moloney, M. M. (2010). Seed-based expression systems for plant molecular 
farming. Plant Biotechnol. J 8: 588-606. 
Borysowski, J. and Gorski, A. (2010). Fusion to cell-penetrating peptides will enable lytic 
enzymes to kill intracellular bacteria. Med. Hypotheses 74: 164-166. 
Bramley, A.J. and Foster, R. (1990). Effects of lysostaphin on Staphylococcus aureus infections 
of the mouse mammary gland. Res. Vet. Sci. 49: 120-121. 
Briers, Y., Volckaert, G., Cornelissen, A., Lagaert, S., Michiels, C.W., Hertveldt, K., and Lavigne, 
R. (2007). Muralytic activity and modular structure of the endolysins of Pseudomonas 
aeruginosa bacteriophages phiKZ and EL. Mol. Microbiol. 65: 1334-1344. 
Briers, Y., Cornelissen, A., Aertsen, A., Hertveldt, K., Michiels, C.W., Volckaert, G. and Lavigne, 
R. (2008). Analysis of outer membrane permeability of Pseudomonas aeruginosa and 
bactericidal activity of endolysins KZ144 and EL188 under high hydrostatic pressure. FEMS 
Microbiol. Lett. 280: 113-119. 
Briers, Y., Schmelcher, M., Loessner, M.J., Hendrix, J., Engelborghs, Y., Volckaert, G., and 
Lavigne, R. (2009). The high-affinity peptidoglycan binding domain of Pseudomonas phage 
endolysin KZ144. Biochem. Biophys. Res. Commun. 383: 187-191. 
Briers, Y., Walmagh, M., and Lavigne, R. (2011). Use of bacteriophage endolysin EL188 and 
outer membrane permeabilizers against Pseudomonas aeruginosa. J. Appl. Microbiol. 
Bustamante, N., Campillo, N.E., Garcia, E., Gallego, C., Pera, B., Diakun, G.P., Saiz, J.L., 
Garcia, P., Diaz, J.F., and Menendez, M. (2010). Cpl-7, a lysozyme encoded by a 
pneumococcal bacteriophage with a novel cell wall-binding motif. J Biol. Chem. 285: 33184-
33196. 
49 
 
Callewaert, L., Walmagh, M., Michiels, C.W., and Lavigne, R. (2010). Food applications of 
bacterial cell wall hydrolases. Curr. Opin. Biotechnol. 22:164-171, 
Cheng, Q., Nelson, D., Zhu, S., and Fischetti, V.A. (2005). Removal of group B streptococci 
colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob. 
Agents Chemother. 49: 111-117. 
Cheng, Q. and Fischetti, V.A. (2007). Mutagenesis of a bacteriophage lytic enzyme PlyGBS 
significantly increases its antibacterial activity against group B streptococci. Appl. Microbiol. 
Biotechnol. 74: 1284-1291. 
Chun, W. and Hancock, R.E. (2000). Action of lysozyme and nisin mixtures against lactic acid 
bacteria. Int J Food Microbiol 60: 25-32. 
Climo, M.W., Patron, R.L., Goldstein, B.P., and Archer, G.L. (1998). Lysostaphin treatment of 
experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob. 
Agents Chemother. 42: 1355-1360. 
Climo, M.W., Ehlert, K. and Archer, G.L. (2001). Mechanism and suppression of lysostaphin 
resistance in oxacillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45: 
1431-1437. 
Croux, C., Ronda, C., Lopez, R., and Garcia, J.L. (1993a). Interchange of functional domains 
switches enzyme specificity: construction of a chimeric pneumococcal-clostridial cell wall lytic 
enzyme. Mol. Microbiol. 9: 1019-1025. 
Croux, C., Ronda, C., Lopez, R., and Garcia, J.L. (1993b). Role of the C-terminal domain of the 
lysozyme of Clostridium acetobutylicum ATCC 824 in a chimeric pneumococcal-clostridial cell 
wall lytic enzyme. FEBS Lett. 336: 111-114. 
Cui, F., Li, G., Huang, J., Zhang, J., Lu, M., Lu, W., Huan, J., and Huang, Q. (2011). 
Development of chitosan-collagen hydrogel incorporated with lysostaphin (CCHL) burn dressing 
with anti-methicillin-resistant Staphylococcus aureus and promotion wound healing properties. 
Drug Deliv. 18: 173-180. 
Dajcs, J.J., Hume, e.b., Moreau, J.M., Caballero, A.R., Cannon, B.M. and O'Callaghan, R.J. 
(2000). Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the 
rabbit(1). Am. J. Ophthalmol. 130: 544. 
Dajcs, J.J., Thibodeaux, B.A., Hume, E.B., Zheng, X., Sloop, G.D. and O'Callaghan, R.J. 
(2001). Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus 
endophthalmitis in the rabbit. Curr. Eye Res. 22: 451-457. 
Dajcs, J.J., Austin, M.S., Sloop, G.D., Moreau, J.M., Hume, E.B., Thompson, H.W., McAleese, 
F.M., Foster, T.J, and O'Callaghan, R.J. (2002). Corneal pathogenesis of Staphylococcus 
aureus strain Newman. Invest Ophthalmol Vis Sci 43: 1109-1115. 
Daniel, A., Euler, C., Collin, M., Chahales, P., Gorelick, K.J. and Fischetti, V.A. (2010). 
Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-
resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 54: 1603-1612. 
50 
 
Davis, K.M. and Weiser, J.N. (2011). Modifications to the peptidoglycan backbone help bacteria 
to establish infection. Infect. Immun. 79: 562-570. 
DeHart, H.P., Heath, H.E., Heath, L.S., LeBlanc, P.A. and Sloan, G.L. (1995). The lysostaphin 
endopeptidase resistance gene (epr) specifies modification of peptidoglycan cross bridges in 
Staphylococcus simulans and Staphylococcus aureus. Appl. Environ. Microbiol. 61: 1475-1479. 
Delbruck, M. (1940). The Growth of Bacteriophage and Lysis of the Host. J. Gen. Physiol 23: 
643-660. 
Desbois, A.P., Lang, S., Gemmell, C.G., and Coote, P.J. (2010). Surface disinfection properties 
of the combination of an antimicrobial peptide, ranalexin, with an endopeptidase, lysostaphin, 
against methicillin-resistant Staphylococcus aureus (MRSA). J. Appl. Microbiol. 108: 723-730. 
Deutsch, S.M., Guezenec, S., Piot, M., Foster, S., and Lortal,S. (2004). Mur-LH, the broad-
spectrum endolysin of Lactobacillus helveticus temperate bacteriophage phi-0303. Appl. 
Environ. Microbiol. 70: 96-103. 
Dhalluin, A., Bourgeois, I., Pestel-Caron, M., Camiade, E., Raux, G., Courtin, P., Chapot-
Chartier, M.P., and Pons,J.L. (2005). Acd, a peptidoglycan hydrolase of Clostridium difficile with 
N-acetylglucosaminidase activity. Microbiology 151: 2343-2351. 
Diaz, E., Lopez, R., and Garcia, J.L. (1990). Chimeric phage-bacterial enzymes: a clue to the 
modular evolution of genes. Proc. Natl. Acad. Sci. U. S. A 87: 8125-8129. 
Diaz, E., Lopez, R., and Garcia, J.L. (1991). Chimeric pneumococcal cell wall lytic enzymes 
reveal important physiological and evolutionary traits. J. Biol. Chem. 266: 5464-5471. 
Djurkovic, S., Loeffler, J.M., and Fischetti, V.A. (2005). Synergistic killing of Streptococcus 
pneumoniae with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin depends on 
the level of penicillin resistance. Antimicrob. Agents Chemother. 49: 1225-1228. 
Donlan, R.M. (2008). Biofilms on central venous catheters: is eradication possible? Curr. Top. 
Microbiol Immunol 322: 133-161. 
Donovan, D.M., Dong, S., Garrett, W., Rousseau, G.M. Moineau, S., and Pritchard, D.G. 
(2006a). Peptidoglycan hydrolase fusions maintain their parental specificities. Appl. Environ. 
Microbiol. 72: 2988-2996. 
Donovan, D.M., Foster-Frey, J., Dong, S., Rousseau, G.M., Moineau, S., and Pritchard, D.G. 
(2006b). The cell lysis activity of the Streptococcus agalactiae bacteriophage B30 endolysin 
relies on the cysteine, histidine-dependent amidohydrolase/peptidase domain. Appl. Environ. 
Microbiol. 72: 5108-5112. 
Donovan, D.M., Lardeo, M., and Foster-Frey, J. (2006c). Lysis of staphylococcal mastitis 
pathogens by bacteriophage phi11 endolysin. FEMS Microbiol. Lett. 265: 133-139. 
Donovan, D.M. and Foster-Frey, J. (2008). LambdaSa2 prophage endolysin requires Cpl-7-
binding domains and amidase-5 domain for antimicrobial lysis of streptococci. FEMS Microbiol 
Lett. 287: 22-33.  
51 
 
Donovan, D.M., Becker, S.C., Dong, S., Baker, J.R., Foster-Frey, J., and Pritchard, D.G. (2009). 
Peptidoglycan hydrolase enzyme fusions for treating multi-drug resistant pathogens. Biotech 
International 21: 6-10. 
 
Duchardt, F., Fotin-Mleczek, M., Schwarz, H., Fischer, R., and Brock, R. (2007). A 
comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic. 8: 
848-866. 
During, K., Porsch, P., Fladung, M., and Lorz, H. (1993). Transgenic potato plants resistant to 
the phytopathogenic bacterium Erwinia carotovora.  The Plant Journal 3: 587-598. 
Dziarski, R. and Gupta, D. (2006). The peptidoglycan recognition proteins (PGRPs). Genome 
Biol. 7: 232. 
Emori, T.G. and Gaynes, R.P. (1993). An overview of nosocomial infections, including the role 
of the microbiology laboratory. Clin Microbiol Rev. 6: 428-442. 
Entenza, J.M., Loeffler, J.M., Grandgirard, D., Fischetti, V.A. and Moreillon, P. (2005). 
Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae 
endocarditis in rats. Antimicrob. Agents Chemother. 49: 4789-4792. 
Fenton, M., Casey, P.G., Hill, C., Gahan, C.G., Ross, R.P., McAuliffe, O., O'Mahony, J., Maher, 
F., and Coffey, A. (2010). The truncated phage lysin CHAP(k) eliminates Staphylococcus 
aureus in the nares of mice. Bioeng. Bugs. 1: 404-407. 
Filatova, L.Y., Becker, S.C., Donovan, D.M., Gladilin, A.K., and Klyachko, N.L. (2010). LysK, the 
enzyme lysing Staphylococcus aureus cells: specific kinetic features and approaches towards 
stabilization. Biochimie 92: 507-513. 
Firczuk, M., Mucha, A., and Bochtler, M. (2005). Crystal structures of active LytM. J. Mol. Biol. 
354: 578-590. 
Firczuk, M., and Bochtler, M. (2007). Folds and activities of peptidoglycan amidases. FEMS 
Microbiol. Rev. 31: 676-691. 
Fischetti, V.A. (2005). Bacteriophage lytic enzymes: novel anti-infectives. Trends Microbiol. 13: 
491-496. 
Fischetti, V.A., Zabriskie, J.B., and Gotschlich, E.C. (1972). Physical, chemical, and biological 
properties of type 6 M-protein extracted with purified streptococcal phage-associated lysin. in 
Fifth International Symposium on Streptococcus pyogenes (ed. M.J.Haverkorn), pp. 26. 
Excerpta Medica, Amsterdam. 
Fischetti, V.A., Nelson, D., and Schuch, R. (2006). Reinventing phage therapy: are the parts 
greater than the sum? Nat. Biotechnol. 24: 1508-1511. 
Foley, S., Bruttin, A., and Brussow, H. (2000). Widespread distribution of a group I intron and its 
three deletion derivatives in the lysin gene of Streptococcus thermophilus bacteriophages. J 
Virol. 74: 611-618. 
52 
 
Fujinami, Y., Hirai, Y., Sakai, I., Yoshino, M., and Yasuda, J. (2007). Sensitive detection of 
Bacillus anthracis using a binding protein originating from gamma-phage. Microbiol. Immunol. 
51: 163-169. 
Fujiwara, T., Aoki, S., Komatsuzawa, H., Nishida, T., Ohara, M., Suginaka, H., and Sugai, M. 
(2005). Mutation analysis of the histidine residues in the glycylglycine endopeptidase ALE-1. J. 
Bacteriol. 187: 480-487. 
Fukushima, T., Yao, Y., Kitajima, T., Yamamoto, H., and Sekiguchi, J. (2007). Characterization 
of new L, D-endopeptidase gene product CwlK (previous YcdD) that hydrolyzes peptidoglycan 
in Bacillus subtilis. Mol. Genet. Genomics 278: 371-383. 
Fukushima, T., Kitajima, T., Yamaguchi, H., Ouyang, Q., Furuhata, K., Yamamoto, H., Shida, T., 
and Sekiguchi, J. (2008). Identification and characterization of novel cell wall hydrolase CwlT: a 
two-domain autolysin exhibiting n-acetylmuramidase and DL-endopeptidase activities. J Biol. 
Chem. 283: 11117-11125. 
Fux, C.A., Stooodley, P., Hall-Stoodley, L., and Costerton, J.W. (2003). Bacterial biofilms: a 
diagnostic and therapeutic challenge. Expert Rev. Anti. Infect. Ther. 1: 667-683. 
Gaeng, S., Scherer, S., Neve, H., and Loessner, M.J. (2000). Gene cloning and expression and 
secretion of Listeria monocytogenes bacteriophage-lytic enzymes in Lactococcus lactis. Appl. 
Environ. Microbiol. 66: 2951-2958. 
Garcia, J.L., Garcia, E., Arraras, A., Garcia, P., Ronda, C., and Lopez, R. (1987). Cloning, 
purification, and biochemical characterization of the pneumococcal bacteriophage Cp-1 lysin. J 
Virol. 61: 2573-2580. 
Garcia, P., Garcia, J.L., Garcia, E., Sanchez-Puelles, J.M., and Lopez, R. (1990). Modular 
organization of the lytic enzymes of Streptococcus pneumoniae and its bacteriophages. Gene. 
86: 81-88. 
Garcia, P., Martinez, B., Rodriguez, L., and Rodriguez, A. (2010). Synergy between the phage 
endolysin LysH5 and nisin to kill Staphylococcus aureus in pasteurized milk. Int. J. Food 
Microbiol. 141: 151-155. 
Garcia, P., Rodriguez, L.,  Rodriguez, A., and Martinez, B. (2010). Food biopreservation: 
promising strategies using bacteriocins, bacteriophages and endolysins. Trends in Food 
Science and Technology 21: 373-382. 
Garcia-del, P.F. and Finlay, B.B. (1995). The varied lifestyles of intracellular pathogens within 
eukaryotic vacuolar compartments. Trends Microbiol. 3: 373-380. 
Graham, S. and Coote, P.J. (2007). Potent, synergistic inhibition of Staphylococcus aureus 
upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide 
ranalexin. J. Antimicrob. Chemother. 59: 759-762. 
Grandgirard, D., Loeffler, J.M., Fischetti, V.A., and Leib, S.L. (2008). Phage lytic enzyme Cpl-1 
for antibacterial therapy in experimental pneumococcal meningitis. J Infect Dis 197: 1519-1522. 
53 
 
Grundling, A., Missiakas, D.M., and Schneewind, O. (2006). Staphylococcus aureus mutants 
with increased lysostaphin resistance. J. Bacteriol. 188: 6286-6297. 
Grundling, A. and Schneewind, O. (2006). Cross-linked peptidoglycan mediates lysostaphin 
binding to the cell wall envelope of Staphylococcus aureus. J. Bacteriol. 188: 2463-2472. 
Gu, J., Xu,  W., Lei, L., Huang, J., Feng, X., Sun, C., Du, C., Zuo, J., Li, Y., Du, T., Li, L., and 
Han, W. (2011). LysGH15, a novel bacteriophage lysin, protects a murine bacteremia model 
efficiently against lethal methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol 
49: 111-117. 
Hagens, S. and Loessner, M.J. (2010). Bacteriophage for biocontrol of foodborne pathogens: 
calculations and considerations. Curr. Pharm. Biotechnol. 11: 58-68. 
Hauben, K.J.L., Wuytack, E.Y., Soontjens, C.C.F., and Michiels, C.W. (1996). High-pressure 
transient sensitization of Escherichia coli to lysozyme and nisin by disruption of outer-membrane 
permeability. J. Food Protection 59: 350-355. 
Hermoso, J.A., Monterroso, B., Albert, A., Galan, B., Ahrazem, O., Garcia, P., Martinez-Ripoll, 
M., Garcia, J.L., and Menendez, M. (2003). Structural basis for selective recognition of 
pneumococcal cell wall by modular endolysin from phage Cp-1. Structure. 11: 1239-1249. 
Hermoso, J.A., Garcia, J.L., and Garcia, P. (2007). Taking aim on bacterial pathogens: from 
phage therapy to enzybiotics. Curr. Opin. Microbiol. 10: 461-472. 
Holtje, J.V. and Tomasz, A. (1975). Lipoteichoic acid: a specific inhibitor of autolysin activity in 
Pneumococcus. Proc. Natl. Acad. Sci. U. S. A 72: 1690-1694. 
Hoopes, J.T., Stark, C.J., Kim, H.A.,Sussman, D.J., Donovan, D.M., and Nelson, D.C. (2009). 
Use of a bacteriophage lysin, PlyC, as an enzyme disinfectant against Streptococcus equi. Appl. 
Environ. Microbiol. 75: 1388-1394. 
Horgan, M., O'Flynn, G., Garry, J., Cooney, J., Coffey, A., Fitzgerald, J.F., Ross, R.P., and 
McAuliffe, O. (2009). Phage lysin LysK can be truncated to its CHAP domain and retain lytic 
activity against live antibiotic-resistant staphylococci. Appl Environ Microbiol. 75: 872-874. 
Huard, C., Miranda, G., Wessner, F., Bolotin, A., Hansen, J., Foster, S.J., and Chapot-Chartier, 
M.P. (2003). Characterization of AcmB, an N-acetylglucosaminidase autolysin from Lactococcus 
lactis. Microbiology 149: 695-705. 
Imbuluzqueta, E., Gamazo, C., Ariza, J., and Blanco-Prieto, M.J. (2010). Drug delivery systems 
for potential treatment of intracellular bacterial infections. Front Biosci. 15: 397-417. 
Inouye, M., Arnheim, N., and Sternglanz, R. (1973). Bacteriophage T7 lysozyme is an N-
acetylmuramyl-L-alanine amidase. J Biol. Chem. 248: 7247-7252. 
Ito, Y., Kwon, O.H., Ueda, M., Tanaka, A., and Imanishi, Y. (1997). Bactericidal activity of 
human lysozymes carrying various lengths of polyproline chain at the C-terminus. FEBS Lett. 
415: 285-288. 
54 
 
Jado, I., Lopez, R., Garcia, E., Fenoll, A., Casal, J., and Garcia, P. (2003). Phage lytic enzymes 
as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. 
J. Antimicrob. Chemother. 52: 967-973. 
Joliot, A. and Prochiantz, A. (2004). Transduction peptides: from technology to physiology. Nat. 
Cell Biol. 6: 189-196. 
Jones, R.N., Barry, A.L., Gavan, T.L., and Washington, J.A. II (1985). Susceptibility tests: 
microdilution and macrodilution broth procedures. in Manual of clinical microbiology (ed. 
A.Balows, J.W.J.Hausler, and H.J.Shadomy), pp. 972-977. American Society for Microbiology, 
Washington D.C. 
Joris, B., Englebert, S., Chu, C.P., Kariyama, R., neo-Moore, L., Shockman, G.D., and 
Ghuysen, J.M. (1992). Modular design of the Enterococcus hirae muramidase-2 and 
Streptococcus faecalis autolysin. FEMS Microbiol Lett. 70: 257-264. 
Kasparek, P., Pantucek, R., Kahankova, J., Ruzickova, V., and Doskar, J. (2007). Genome 
rearrangements in host-range mutants of the polyvalent staphylococcal bacteriophage 812. 
Folia Microbiol. (Praha) 52: 331-338. 
Keren, I., Kaldalu, N., Spoering, A., Wang, Y., and Lewis, K. (2004). Persister cells and 
tolerance to antimicrobials. FEMS Microbiol Lett. 230: 13-18. 
Kerr, D.E., Plaut, K., Bramley, A.J., Williamson, C.M., Lax, A.J., Moore, K., Wells, K.D., and 
Wall, R.J. (2001). Lysostaphin expression in mammary glands confers protection against 
staphylococcal infection in transgenic mice. Nat. Biotechnol. 19: 66-70. 
Kikkawa, H., Fujinami, Y., Suzuki, S., and Yasuda, J. (2007). Identification of the amino acid 
residues critical for specific binding of the bacteriolytic enzyme of gamma-phage, PlyG, to 
Bacillus anthracis. Biochem Biophys Res Commun. 363: 531-535. 
Kikkawa, H.S., Ueda, T., Suzuki, S., and Yasuda, J. (2008). Characterization of the catalytic 
activity of the gamma-phage lysin, PlyG, specific for Bacillus anthracis. FEMS Microbiol Lett. 
286: 236-240. 
Kim, W.S., Salm, H., and Geider, K. (2004). Expression of bacteriophage phiEa1h lysozyme in 
Escherichia coli and its activity in growth inhibition of Erwinia amylovora. Microbiology 150: 
2707-2714. 
Kiri, N., Archer, G., and Climo, M.W., (2002). Combinations of lysostaphin with beta-lactams are 
synergistic against oxacillin-resistant Staphylococcus epidermidis. Antimicrob. Agents 
Chemother. 46: 2017-2020. 
Kokai-Kun,J .F., Walsh, S.M., Chanturiya, T., and Mond, J.J. (2003). Lysostaphin cream 
eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob Agents 
Chemother 47: 1589-1597. 
Kokai-Kun, J.F., Chanturiya, T., and Mond, J.J. (2007). Lysostaphin as a treatment for systemic 
Staphylococcus aureus infection in a mouse model. J Antimicrob Chemother. 60: 1051-1059. 
55 
 
Kokai-Kun, J.F., Chanturiya, T., and Mond, J.J.  2009. Lysostaphin eradicates established 
Staphylococcus aureus biofilms in jugular vein catheterized mice. J Antimicrob Chemother 64: 
94-100. 
Korndorfer, I.P., Danzer, J., Schmelcher, M., Zimmer, M., Skerra, A., and Loessner, M.J. (2006). 
The crystal structure of the bacteriophage PSA endolysin reveals a unique fold responsible for 
specific recognition of Listeria cell walls. J Mol. Biol. 364: 678-689. 
Korndorfer, I.P., Kanitz, A., Danzer, J., Zimmer, M., Loessner, M.J., and Skerra, A. (2008). 
Structural analysis of the L-alanoyl-D-glutamate endopeptidase domain of Listeria 
bacteriophage endolysin Ply500 reveals a new member of the LAS peptidase family. Acta 
Crystallogr. D. Biol. Crystallogr. 64: 644-650. 
Krause, R.M. (1957). Studies on bacteriophages of hemolytic streptococci. I. Factors influencing 
the interaction of phage and susceptible host cell. J Exp. Med 106: 365-384. 
Kretzer, J.W., Lehmann, R., Schmelcher, M., Banz, M., Kim, K.P., Korn, C.., and Loessner, M.J. 
(2007). Use of high-affinity cell wall-binding domains of bacteriophage endolysins for 
immobilization and separation of bacterial cells. Appl. Environ. Microbiol. 73: 1992-2000. 
Kusuma, C. and Kokai-Kun, J. (2005). Comparison of four methods for determining lysostaphin 
susceptibility of various strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 
3256-3263. 
Kusuma, C., Jadanova, A., Chanturiya, T., and Kokai-Kun, J.F. (2007). Lysostaphin-resistant 
variants of Staphylococcus aureus demonstrate reduced fitness in vitro and in vivo. Antimicrob. 
Agents Chemother. 51: 475-482. 
Lai, M.J., Lin, N.T., Hu, A., Soo, P.C. Chen, L.K., Chen, L.H., and Chang, K.C. (2011). 
Antibacterial activity of Acinetobacter baumannii phage varphiAB2 endolysin (LysAB2) against 
both Gram-positive and Gram-negative bacteria. Appl. Microbiol. Biotechnol. 
Lewis, K. (2001). Riddle of biofilm resistance. Antimicrob Agents Chemother. 45: 999-1007. 
Lindsay, J.A. (2008). Staphylococcus Molecular Genetics. Caister Academic Press, Norfolk, UK. 
Loeffler, J.M., Nelson, D., and Fischetti, V.A. (2001). Rapid killing of Streptococcus pneumoniae 
with a bacteriophage cell wall hydrolase. Science 294: 2170-2172. 
Loeffler, J.M., Djurkovic, S., and Fischetti, V.A. (2003). Phage lytic enzyme Cpl-1 as a novel 
antimicrobial for pneumococcal bacteremia. Infect. Immun. 71: 6199-6204. 
Loeffler, J.M. and Fischetti, V.A. (2003). Synergistic lethal effect of a combination of phage lytic 
enzymes with different activities on penicillin-sensitive and -resistant Streptococcus pneumoniae 
strains. Antimicrob. Agents Chemother. 47: 375-377. 
Loessner, M.J., Schneider, A., and Scherer, S. (1995a). A new procedure for efficient recovery 
of DNA, RNA, and proteins from Listeria cells by rapid lysis with a recombinant bacteriophage 
endolysin. Appl Environ Microbiol 61: 1150-1152. 
56 
 
Loessner, M.J., Wendlinger, G., and Scherer, S. (1995b). Heterogeneous endolysins in Listeria 
monocytogenes bacteriophages: a new class of enzymes and evidence for conserved holin 
genes within the siphoviral lysis cassettes. Mol. Microbiol 16: 1231-1241. 
Loessner, M.J., Gaeng, S., Wendlinger, G., Maier, S.K., and Scherer, S. (1998). The two-
component lysis system of Staphylococcus aureus bacteriophage Twort: a large TTG-start holin 
and an associated amidase endolysin. FEMS Microbiol. Lett. 162: 265-274. 
Loessner, M.J., Kramer, K., Ebel, F., and Scherer, S. (2002). C-terminal domains of Listeria 
monocytogenes bacteriophage murein hydrolases determine specific recognition and high-
affinity binding to bacterial cell wall carbohydrates. Mol. Microbiol. 44: 335-349. 
Loessner, M.J. (2005). Bacteriophage endolysins--current state of research and applications. 
Curr. Opin. Microbiol. 8: 480-487. 
Lopez, R., Garcia, E., Garcia, P., and Garcia, J.L. (1997). The pneumococcal cell wall 
degrading enzymes: a modular design to create new lysins? Microb Drug Resist. 3: 199-211. 
Lopez, R., Garcia, E., Garcia, P., Ronda, C., and Tomasz, A. (1982). Choline-containing 
bacteriophage receptors in Streptococcus pneumoniae. J Bacteriol. 151: 1581-1590. 
Low, L.Y., Yang, C., Perego, M., Osterman, A., and Liddington, R.C. (2005). Structure and lytic 
activity of a Bacillus anthracis prophage endolysin. J. Biol. Chem. 280: 35433-35439. 
Lu, J.Z., Fujiwara, T., Komatsuzawa, H., Sugai, M., and Sakon, J. (2006). Cell wall-targeting 
domain of glycyl-glycine endopeptidase distinguishes among peptidoglycan cross-bridges. J. 
Biol. Chem. 281: 549-558. 
Maga, E.A., Cullor, J.S., Smith, W., Anderson, G.B., and Murray, J.D. (2006a). Human 
lysozyme expressed in the mammary gland of transgenic dairy goats can inhibit the growth of 
bacteria that cause mastitis and the cold-spoilage of milk. Foodborne. Pathog. Dis. 3: 384-392. 
Maga, E.A., Walker, R.K., Anderson, G.B., and Murray, J.D. (2006b). Consumption of milk from 
transgenic goats expressing human lysozyme in the mammary gland results in the modulation 
of intestinal microflora. Transgenic Res 15: 515-519. 
Manoharadas, S., Witte, A., and Blasi, U. (2009). Antimicrobial activity of a chimeric enzybiotic 
towards Staphylococcus aureus. J Biotechnol. 139: 118-123. 
Masschalck, B., Garcia-Graells, C., Van Haver, E., and Michiels, C.W. (2000). Inactivation of 
high pressure resistant Escherichia coli by nisin and lysozyme under high pressure. Innov. Food 
Sci. and Emerg. Technol. 1: -39. 
Masschalck, B. and Michiels, C.W. (2003). Antimicrobial properties of lysozyme in relation to 
foodborne vegetative bacteria. Crit Rev. Microbiol. 29: 191-214. 
Masschalck, B., Van, H.R., and Michiels, C.W. (2001). High pressure increases bactericidal 
activity and spectrum of lactoferrin, lactoferricin and nisin. Int. J. Food Microbiol. 64: 325-332. 
Mayer, M.J., .Narbad, A., and Gasson, M.J. (2008). Molecular characterization of a Clostridium 
difficile bacteriophage and its cloned biologically active endolysin. J. Bacteriol. 190: 6734-6740. 
57 
 
Mayer, M.J., Payne, J., Gasson, M.J., and Narbad, A. (2010). Genomic sequence and 
characterization of the virulent bacteriophage phiCTP1 from Clostridium tyrobutyricum and 
heterologous expression of its endolysin. Appl. Environ. Microbiol. 76: 5415-5422. 
McCullers, J.A., Karlstrom, A., Iverson, A.R., Loeffler, J.M, and Fischetti, V.A. (2007). Novel 
strategy to prevent otitis media caused by colonizing Streptococcus pneumoniae. PLoS Pathog. 
3: e28. 
Mesnage, S., Chau, F., Dubost, L., and Arthur, M. (2008). Role of N-acetylglucosaminidase and 
N-acetylmuramidase activities in Enterococcus faecalis peptidoglycan metabolism. J Biol. 
Chem. 283: 19845-19853. 
Mitchell, G.J., Nelson, D.C. and Weitz, J.S. (2010). Quantifying enzymatic lysis: estimating the 
combined effects of chemistry, physiology and physics. Phys. Biol. 7: 046002. 
Moak, M. and Molineux, I.J. (2004). Peptidoglycan hydrolytic activities associated with 
bacteriophage virions. Mol. Microbiol. 51: 1169-1183. 
Mokrasch, L.C. (1967). Use of 2,4,6-trinitrobenzenesulfonic acid for the coestimation of amines, 
amino acids and proteins in mixtures. Anal Biochem 18: 64-71. 
Monterroso, B., Saiz, J.L., Garcia, P., Garcia, J.L., and Menendez, M. (2008). Insights into the 
structure-function relationships of pneumococcal cell wall lysozymes, LytC and Cpl-1. J Biol. 
Chem. 283: 28618-28628. 
Morita, M., Tanji, Y., Orito, Y., Mizoguchi, K., Soejima, A., and Unno, H. (2001). Functional 
analysis of antibacterial activity of Bacillus amyloliquefaciens phage endolysin against Gram-
negative bacteria. FEBS Lett. 500: 56-59. 
Muyombwe, A., Tanji, Y., and Unno, H. (1999). Cloning and expression of a gene encoding the 
lytic functions of Bacillus amyloliquefaciens phage: Evidence of an auxiliary lysis system. J. 
Biosci. Bioeng. 88: 221-225. 
Nakimbugwe, D., Masschalck, B., Deckers, D., Callewaert, L., Aertsen, A., and Michiels, C.W. 
(2006). Cell wall substrate specificity of six different lysozymes and lysozyme inhibitory activity 
of bacterial extracts. FEMS Microbiol. Lett. 259: 41-46. 
Navarre, W.W., Ton-That, H., Faull, K.F., and Schneewind, O. (1999). Multiple enzymatic 
activities of the murein hydrolase from staphylococcal phage phi11. Identification of a D-alanyl-
glycine endopeptidase activity. J. Biol. Chem. 274: 15847-15856. 
Nelson, D., Loomis, L., and Fischetti, V.A. (2001). Prevention and elimination of upper 
respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. 
Proc. Natl. Acad. Sci. U. S. A 98: 4107-4112. 
Nelson, D., Schuch, R.,  Zhu, S., Tscherne, D.M., and Fischetti, V.A. (2003). Genomic 
sequence of C1, the first streptococcal phage. J Bacteriol. 185: 3325-3332. 
Nelson, D., Schuch, R., Chahales, P., Zhu, S., and Fischetti, V.A. (2006). PlyC: a multimeric 
bacteriophage lysin. Proc. Natl. Acad. Sci. U. S. A 103: 10765-10770. 
58 
 
O'Flaherty, S., Coffey, A., Edwards, R., Meaney, W., Fitzgerald, G.F., and Ross, R.P. (2004). 
Genome of staphylococcal phage K: a new lineage of Myoviridae infecting gram-positive 
bacteria with a low G+C content. J Bacteriol. 186: 2862-2871. 
O'Flaherty, S., Coffey, A., Meaney, W., Fitzgerald, G.F., and Ross, R.P.  (2005). The 
recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant 
staphylococci, including methicillin-resistant Staphylococcus aureus. J. Bacteriol. 187: 7161-
7164. 
O'Flaherty, S., Ross, R.P., and Coffey, A. (2009). Bacteriophage and their lysins for elimination 
of infectious bacteria. FEMS Microbiol. Rev. 33: 801-819. 
Obeso, J.M., Martinez, B., Rodriguez, A., and Garcia, P. (2008). Lytic activity of the recombinant 
staphylococcal bacteriophage PhiH5 endolysin active against Staphylococcus aureus in milk. 
Int. J. Food Microbiol. 128: 212-218. 
Oey, M., Lohse, M., Kreikemeyer, B., and Bock, R. (2009). Exhaustion of the chloroplast protein 
synthesis capacity by massive expression of a highly stable protein antibiotic. Plant J 57: 436-
445. 
Oldham, E.R. and Daley, M.J. (1991). Lysostaphin: use of a recombinant bactericidal enzyme 
as a mastitis therapeutic. J. Dairy Sci. 74: 4175-4182. 
Orito, Y., Morita, M., Hori, K., Unno, H., and Tanji, Y. (2004). Bacillus amyloliquefaciens phage 
endolysin can enhance permeability of Pseudomonas aeruginosa outer membrane and induce 
cell lysis. Appl. Microbiol. Biotechnol. 65: 105-109. 
Palmer, K.L., Kos, V.N., and Gilmore, M.S. (2010). Horizontal gene transfer and the genomics 
of enterococcal antibiotic resistance. Curr. Opin. Microbiol. 13: 632-639. 
Pangule, R.C., Brooks, S.J., Dinu, C.Z., Bale, S.S., Salmon, S.L., Zhu, G., Metzger, D.W., Kane, 
R.S., and Dordick, J.S. (2010). Antistaphylococcal nanocomposite films based on enzyme-
nanotube conjugates. ACS Nano. 4: 3993-4000. 
Paradis-Bleau, C., Cloutier, I., Lemieux, L., Sanschagrin, F., Laroche, J., Auger, M., Garnier, A., 
and Levesque, R.C. (2007). Peptidoglycan lytic activity of the Pseudomonas aeruginosa phage 
phiKZ gp144 lytic transglycosylase. FEMS Microbiol. Lett. 266: 201-209. 
Park, J.T. and Johnson, M.J. (1949). A submicrodetermination of glucose. J Biol. Chem. 181: 
149-151. 
Pastagia, M., Euler, C., Chahales, P., Fuentes-Duculan, J., Krueger, J.G., and Fischetti, V.A, 
(2011). A Novel Chimeric Lysin Shows Superiority to Mupirocin for Skin Decolonization of 
Methicillin-Resistant and -Sensitive Staphylococcus aureus Strains. Antimicrob. Agents 
Chemother. 55: 738-744. 
Patron, R.L., Climo, M.W., Goldstein, B.P., and Archer, G.L. (1999). Lysostaphin treatment of 
experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced 
susceptibility to vancomycin. Antimicrob. Agents Chemother. 43: 1754-1755. 
59 
 
Ponting, C.P., Aravind, L., Schultz, J., Bork, P., and Koonin, E.V. (1999). Eukaryotic signalling 
domain homologues in archaea and bacteria. Ancient ancestry and horizontal gene transfer. J. 
Mol. Biol. 289: 729-745. 
Porter, C.J., Schuch, R., Pelzek, A.J., Buckle, A.M., McGowan, S., Wilce, M.C.,Rossjohn, J., 
Russell, R., Nelson, D., Fischetti, V.A. and Whisstock, J.C. (2007). The 1.6 A crystal structure of 
the catalytic domain of PlyB, a bacteriophage lysin active against Bacillus anthracis. J. Mol. Biol. 
366: 540-550. 
Pritchard, D.G., Dong, S., Baker, J.R., and Engler, J.A. (2004). The bifunctional peptidoglycan 
lysin of Streptococcus agalactieae bacteriophage B30. Microbiology 150: 2079-2087. 
Pritchard, D.G., Dong, S., Kirk, M.C., Cartee, R.T., and Baker, J.R. (2007). LambdaSa1 and 
LambdaSa2 Prophage Lysins of Streptococcus agalactiae. Appl. Environ. Microbiol. 73: 7150-
7154. 
Rashel, M., Uchiyama, J., Ujihara, T., Uehara, Y., Kuramoto, S., Sugihara, S., Yagyu, K., 
Muraoka, A., Sugai, M., Hiramatsu, K., Honke, K., and Matsuzaki, S. (2007). Efficient 
elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from 
bacteriophage phi MR11. J. Infect. Dis. 196: 1237-1247. 
Rigden, D.J., Jedrzejas, M.J., and Galperin, M.Y. (2003). Amidase domains from bacterial and 
phage autolysins define a family of gamma-D,L-glutamate-specific amidohydrolases. Trends 
Biochem. Sci. 28: 230-234. 
Rossolini, G.M., Mantengoli, E., Montagnani, F., and Pollini, S. (2010). Epidemiology and 
clinical relevance of microbial resistance determinants versus anti-Gram-positive agents. Curr. 
Opin. Microbiol. 13: 582-588. 
Sahl, H.G. and Bierbaum, G. (2008). Multiple activities in natural antimicrobials. Microbe 3: 467-
473. 
Sanz, J.M., Garcia, P. and Garcia, J.L. (1996). Construction of a multifunctional pneumococcal 
murein hydrolase by module assembly. Eur. J. Biochem. 235: 601-605. 
Sass, P. and Bierbaum, G. (2007). Lytic Activity of Recombinant Bacteriophage {phi}11 and 
{phi}12 Endolysins on Whole Cells and Biofilms of Staphylococcus aureus. Appl. Environ. 
Microbiol. 73: 347-352. 
Satake, K., Okuyama, T.,Ohashi, M., and Shinoda, T. (1960). The spectrophotometric 
determination of amine, amino acid and peptide with 2,4,6,-trinitrobenzene 1-sulfonic acid. J. 
Biochem 47: 654-660. 
Sawhney, R. and Berry, V.  (2009). Bacterial biofilm formation, pathogenicity, diagnostics and 
control: An overview. Indian J Med Sci 63: 313-321. 
Schaffner, W., Melly, M.A.,  and Koenig, M.G. (1967). Lysostaphin: an enzymatic approach to 
staphylococcal disease. II. In vivo studies. Yale J. Biol. Med. 39: 230-244. 
Scheurwater, E.M., and Clarke, A.J. (2008). The C-terminal domain of Escherichia coli YfhD 
functions as a lytic transglycosylase. J. Biol. Chem. 283: 8363-8373. 
60 
 
Schindler, C.A. and Schuhardt, V.T. (1964). Lysostaphin: a new bacteriolytic agent for the 
Staphylococcus. Proc. Natl. Acad. Sci. U. S. A 51: 414-421. 
Schleifer, K.H. and Kandler,O. (1972). Peptidoglycan types of bacterial cell walls and their 
taxonomic implications. Bacteriol. Rev. 36: 407-477. 
Schmelcher, M., Shabarova, T.,  Eugster, M.R., Eichenseher, F., Tchang, V.S., Banz, M., and 
Loessner, M.J. (2010). Rapid multiplex detection and differentiation of Listeria cells by use of 
fluorescent phage endolysin cell wall binding domains. Appl. Environ. Microbiol. 76: 5745-5756. 
Schmelcher, M., Tchang, V.S., and Loessner, M.J. (2011). Domain shuffling and module 
engineering of Listeria phage endolysins for enhanced lytic activity and binding affinity. Microb. 
Biotechnol. 
Schuch, R  Nelson, D., and Fischetti, V.A. (2002). A bacteriolytic agent that detects and kills 
Bacillus anthracis. Nature 418: 884-889. 
Schuch, R., Fischetti, V.A. and Nelson, D.C. (2009). A genetic screen to identify bacteriophage 
lysins. Methods Mol. Biol. 502: 307-319. 
Seltman, G. and Holst, O. (2001). The bacterial cell wall. Springer Verlag, Berlin. 
Sheehan, M.M., Garcia, J.L, Lopez, R., and Garcia, P. (1996). Analysis of the catalytic domain 
of the lysin of the lactococcal bacteriophage Tuc2009 by chimeric gene assembling. FEMS 
Microbiol. Lett. 140: 23-28. 
Silva-Martin, N., Molina, R., Angulo, I., Mancheno, J.M., Garcia, P., and Hermoso, J.A. (2010). 
Crystallization and preliminary crystallographic analysis of the catalytic module of endolysin 
from Cp-7, a phage infecting Streptococcus pneumoniae. Acta Crystallogr. Sect. F. Struct. Biol. 
Cryst. Commun. 66: 670-673. 
Simmons, M., Donovan, D.M., Siragusa, G.R., and Seal, B.S. (2010). Recombinant expression 
of two bacteriophage proteins that lyse Clostridium perfringens and share identical sequences in 
the C-terminal cell wall binding domain of the molecules but are dissimilar in their N-terminal 
active domains. J. Agric. Food Chem. 58: 10330-10337. 
Son, J.S., Lee, S.J., Jun, S.Y., Yoon, S.J., Kang, S.H., Paik, H.R., Kang, J.O., and Choi, Y.J. 
(2010). Antibacterial and biofilm removal activity of a podoviridae Staphylococcus aureus 
bacteriophage SAP-2 and a derived recombinant cell-wall-degrading enzyme. Appl. Microbiol. 
Biotechnol. 86: 1439-1449. 
Spiro, R.G. (1966). Analysis of sugars found in glycoproteins. Methods Enzymol. 8: 3-26. 
Splith, K. and Neundorf, I. (2011). Antimicrobial peptides with cell-penetrating peptide properties 
and vice versa. Eur. Biophys. J. 
Stark, C.J., Hoopes, J.T., Bonocoroa, R.P. and Nelson, D.C. (2010). Bacteriophage Lytic 
Enzymes as Antimicrobials. in Bacteriophage in the Detection and Control of Foodborne 
Pathogens (ed. P.V.Sabour and M.W.Griffith), pp. 137-156. ASM Press, Washington, D.C. 
61 
 
Steen, A., van Schalkwijk, S., Buist, G., Twigt, M., Szeliga, W., Meijer, W., Kuipers, O.P., Kok, 
J., and Hugenholz, J. (2007). Lytr, a phage-derived amidase is most effective in induced lysis of 
Lactococcus lactis compared with other lactococcal amidases and glucosaminidases. Int. Dairy 
J. 17: 926-936. 
Stentz, CR., Bongaerts, R.J., Gunning, A.P., Gasson, M., and Shearman, C. (2010). Controlled 
release of protein from viable Lactococcus lactis cells. Appl. Environ. Microbiol. 76: 3026-3031. 
Sugai, M., Fujiwara, T., Ohta, K., Komatsuzawa, H., Ohara, M., and Suginaka, H. (1997). epr, 
which encodes glycylglycine endopeptidase resistance, is homologous to femAB and affects 
serine content of peptidoglycan cross bridges in Staphylococcus capitis and Staphylococcus 
aureus. J. Bacteriol. 179: 4311-4318. 
Sun, H.C., Xue, F.M., Qian, K., Fang, X.H., Qiu, H.L., Zhang, X.Y., and Yin, Z.H. (2006). 
Intramammary expression and therapeutic effect of a human lysozyme-expressing vector for 
treating bovine mastitis. J. Zhejiang. Univ Sci. B 7: 324-330. 
Tan, Y.P., Giffard, P.M., Barry, D.G., Huston, W.M., and Turner, M.S. (2008). Random 
mutagenesis identifies novel genes involved in the secretion of antimicrobial, cell wall-lytic 
enzymes by Lactococcus lactis. Appl. Environ. Microbiol. 74: 7490-7496. 
Taylor, A. and Gorazdowska, M. (1974). Conversion of murein to non-reducing fragments by 
enzymes from phage lambda and Vi II lysates. Biochim. Biophys. Acta 342: 133-136. 
Thumm, G. and Gotz, F. (1997). Studies on prolysostaphin processing and characterization of 
the lysostaphin immunity factor (Lif) of Staphylococcus simulans biovar staphylolyticus. Mol. 
Microbiol. 23: 1251-1265. 
Tong, J., Wei, H., Liu, X., Hu, W., Bi, M., Wang, Y., Li, Q., and Li, N. (2010). Production of 
recombinant human lysozyme in the milk of transgenic pigs. Transgenic Res. 
Turner, M.S., Waldherr, F., Loessner, M.J., and Giffard, P.M. (2007). Antimicrobial activity of 
lysostaphin and a Listeria monocytogenes bacteriophage endolysin produced and secreted by 
lactic acid bacteria. Syst. Appl. Microbiol. 30: 58-67. 
Vaara, M. (1992). Agents that increase the permeability of the outer membrane. Microbiol. Rev. 
56: 395-411. 
Vasala, A., Valkkila, M., Caldentey, J., and Alatossava, T. (1995). Genetic and biochemical 
characterization of the Lactobacillus delbrueckii subsp. lactis bacteriophage LL-H lysin. Appl 
Environ Microbiol 61: 4004-4011. 
Vazquez-Boland, J.A., Kuhn, M., Berche, P., Chakraborty, T., Dominguez-Bernal, G., Goebel, 
W., Gonzalez-Zorn, B., Wehland, J., and Kreft, J. (2001). Listeria pathogenesis and molecular 
virulence determinants. Clin. Microbiol. Rev. 14: 584-640. 
Vollmer, W. (2008). Structural variation in the glycan strands of bacterial peptidoglycan. FEMS 
Microbiol. Rev. 32: 287-306. 
Walcher, G., Stessl, B., Wagner, M., Eichenseher, F., Loessner, M.J., and IHein, I. (2010). 
Evaluation of paramagnetic beads coated with recombinant Listeria phage endolysin-derived 
62 
 
cell-wall-binding domain proteins for separation of Listeria monocytogenes from raw milk in 
combination with culture-based and real-time polymerase chain reaction-based quantification. 
Foodborne. Pathog. Dis. 7: 1019-1024. 
Walencka, E., Sadowska, B., Rozalska, S., Hryniewicz, W., and Rozalska, B. (2005). 
Lysostaphin as a potential therapeutic agent for staphylococcal biofilm eradication. Pol J 
Microbiol. 54: 191-200. 
Wall, R.J., Powell, A., Paape, M.J., Kerr, D.E., Bannerman, D.D., Pursel, V.G., Wells, K.D., 
Talbot, N., and Hawk, H.W. (2005). Genetically enhanced cows resist intramammary 
Staphylococcus aureus infection. Nat. Biotechnol. 23: 445-451. 
Ward, J.B. (1973). The chain length of the glycans in bacterial cell walls. Biochem. J. 133: 395-
398. 
Weidel, W. and Pelzer, H. (1964). Bagshaped macromolecules --  A new outlook on bacterial 
cell walls. Adv. Enzymol. Relat Areas Mol. Biol. 26: 193-232. 
Whisstock, J.C. and Lesk, A.M. (1999). SH3 domains in prokaryotes. Trends Biochem. Sci. 24: 
132-133. 
Wu, J.A., Kusuma, C., Mond, J.J., and Kokai-Kun, J.F. (2003). Lysostaphin disrupts 
Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. 
Antimicrob. Agents Chemother. 47: 3407-3414. 
Yang, B., Wang, J., Tang, B., Liu, Y., Guo, C., Yang, P., Yu, T., Li, R., Zhao, J., Zhang, L., Dai, 
Y., and Li, N. (2011). Characterization of bioactive recombinant human lysozyme expressed in 
milk of cloned transgenic cattle. PLoS. ONE. 6: e17593. 
Yang, G., Gao, Y., Feng, J., Huang, Y., Li, S., Liu, Y., Liu, C., Fan, M., Shen, B., and Shao, N. 
(2008). C-terminus of TRAP in Staphylococcus can enhance the activity of lysozyme and 
lysostaphin. Acta Biochim. Biophys. Sin. (Shanghai) 40: 452-458. 
Yoong, P., Schuch, R., Nelson, D., and Fischetti, V.A. (2004). Identification of a broadly active 
phage lytic enzyme with lethal activity against antibiotic-resistant Enterococcus faecalis and 
Enterococcus faecium. J Bacteriol. 186: 4808-4812. 
Yoong, P., Schuch, R., Nelson, D., and Fischetti, V.A. (2006). PlyPH, a bacteriolytic enzyme 
with a broad pH range of activity and lytic action against Bacillus anthracis. J. Bacteriol. 188: 
2711-2714. 
Young, R. (1992). Bacteriophage lysis: mechanism and regulation. Microbiol Rev. 56: 430-481. 
Zimmer, M., Vukov, N., Scherer, S., and Loessner, M.J. (2002). The murein hydrolase of the 
bacteriophage phi3626 dual lysis system is active against all tested Clostridium perfringens 
strains. Appl. Environ. Microbiol. 68: 5311-5317. 
 
 
63 
 
 
Figure Legends: 
 
Fig. 1.  Structure of S. aureus bacterial PG and cleavage sites by PG hydrolases.  (A) An 
N-acetylglucosaminidase hydrolyzes the glycan component of the PG on the reducing side of 
GlcNAc.  (B) In contrast, an N-acetylmuramidase (also known as “muramidase” or “lysozyme”) 
hydrolyzes the glycan component of the PG on the reducing side of MurNAc.  Likewise, lytic 
transglycosylases cleave the same bond, but form 1,6 anhydromuramyl intermediates during 
cleavage.  (C) An N-acetylmuramoyl-L-alanine amidase cleaves a critical amide bond between 
the glycan moiety (MurNAc) and the peptide moiety (L-alanine) of the cell wall.  This activity is 
sometimes referred to generically as an “amidase”.  (D,E,F,G) An endopeptidase cleaves an 
amide bond between two amino acids.  This type of activity may occur in the stem peptide of the 
PG, as in the case of the Listeria endolysins, Ply500 and Ply118 (D), or the streptococcal 
endolysin, λSa2 (E).  Alternatively, an endopeptidase can cleave the interpeptide bridge as 
displayed by the staphylococcal endolysin Ф11 (F) or the staphylococcal bacteriocin, 
lysostaphin (G) Note, the structure of the Staphylococcus aureus PG is depicted for illustration 
purposes.  Other bacterial species have interpeptide bridges composed of different amino acids 
or may lack an interpeptide bridge all together.  In these organisms, a meso-diaminopimelic acid 
replaces L-Lys and directly crosslinks to the terminal D-Ala of the opposite peptide chain. 
 
Fig. 2.  Electron spray ionization mass spectrometry determination of LysK and phi80α 
endolysin cut sites in S. aureus PG.    Purified S. aureus PG was digested with LysK and 
phi80α endolysin under identical conditions as described in Becker et al. (Becker et al., 2009).  
The digests were filtered through 5K cutoff ultrafilters and these filtrates were further processed 
through disposable charcoal columns (CarboPak).  The bound muropeptides were eluted with 
50% acetonitrile and subjected to mass spectrometry.   
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Fig. 3.  Staphylococcal PG hydrolase structure. White boxes represent cell wall binding 
domains. SH3b: bacterial Src homology 3 domain (Whisstock and Lesk, 1999;Ponting et al., 
1999); PGRP: Peptidoglycan recognition protein (Dziarski and Gupta, 2006).  Scale bar 
represents the number of amino acids.  * weak PFAM homology;  ** not present in mature 
protein 
 
Fig. 4.  Streptococcal PG hydrolases.  White boxes represent cell wall binding domains. 
ChBD: Choline binding domain (Hermoso et al., 2003); Cpl-7: (Garcia et al., 1990); SH3b: 
bacterial Src homology 3 domain (Whisstock and Lesk, 1999;Ponting et al., 1999). Scale bar 
represents the number of amino acids. 
 
Fig. 5.   Enterococcal PG hydrolases.  LysM: (Bateman and Bycroft, 2000); (Joris et al., 
1992); SH3b: bacterial Src homology 3 domain (Whisstock and Lesk, 1999;Ponting et al., 1999); 
NLP_P60: (Anantharaman and Aravind, 2003). Scale bar represents the number of amino 
acids. 
 
Fig. 6.  A reduction in turbidity equates to reduced bacterial viability.  A.  25 µg of Φ11 
endolysin (construct Φ11-194; (Donovan et al., 2006)) protein (circles) and S. aureus cells alone 
(squares) were monitored for 120 min in a turbidity reduction assay.   B.  Treated (Φ11-194) and 
non-treated (cells alone) turbidity assay samples were serially diluted and at 0, 30 and 120 min. 
plated onto tryptic soy agar plates.   The results shown reflect the CFU/ml of the treated cells 
expressed as a percentage of the viable counts of the untreated control sample.  Error bars = 
SEM.   
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Table 1.   Enterococcal lysins 
 
 
  AA ACCESSION # 
GROUP 1    
endolysin, putative [E. faecalis V583] 433 NP_814147.1 
endolysin [E. faecalis ATCC 29200] 433 ZP_04437810.1 
lysin [E. faecalis DS5] 433 ZP_05562195.1 
lysin [E. faecalis T1] 433 ZP_05423767.1 
lysin [E. faecalis HIP11704] 433 ZP_05568662.1 
endolysin [phage phiFL4A] 433 YP_003347409.1 
endolysin [E. faecalis V583] 433 NP_816427.1 
lysin [E. faecalis AR01/DG] 433 ZP_05593964.1 
endolysin [E. faecalis X98] 433 ZP_05598729.1 
endolysin [phage phiFL1A] 433 YP_003347517.1 
endolysin [phage phiFL2A] 433 YP_003347352.1 
endolysin [phage phiFL1B] 433 ACZ63822.1 
endolysin [phage phiFL1C] 433 ACZ63895.1 
endolysin [phage phiFL2B] 433 ACZ64018.1 
endolysin [E. faecalis T8] 433 ZP_05558876.1 
lysin [E. faecalis JH1] 433 ZP_05573731.1 
GROUP 2     
lysin [E. faecalis Merz96] 419 ZP_05565596.1 
endolysin [E. faecalis R712] 419 ZP_06629599.1 
endolysin [E. faecalis S613] 419 ZP_06631635.1 
endolysin [phage phiEf11] 419 YP_003358816.1 
endolysin [E. faecalis X98] 419 ZP_05599066.1 
endolysin [E. faecalis CH188] 419 ZP_05585395.1 
endolysin [phage phiFL3A] 419 YP_003347625.1 
endolysin [phage phiFL3B] 419 ACZ64148.1 
lysin [E. faecalis JH1] 419 ZP_05572412.1 
lysin [E. faecalis D6] 419 ZP_05581557.1 
GROUP 3     
endolysin [E. faecalis ATCC 29200] 412 ZP_04438395.1 
phage lysin [E. faecalis T1] 412 ZP_05422953.1 
endolysin [E. faecalis V583] 413 NP_815667.1 
phage lysin [E. faecalis HIP11704] 413 ZP_05568908.1 
phage lysin [E. faecalis E1Sol] 413 ZP_05576004.1 
endolysin [E. faecalis TX1322] 413 ZP_04434151.1 
endolysin [E. faecalis CH188] 413 ZP_05584633.1 
phage lysin [E. faecalis ATCC 4200] 1 413 ZP_05476312.1 
endolysin [E. faecalis TUSoD Ef11] 394 ZP_04647652.1 
endolysin [E. faecalis T8] 413 ZP_05559457.1 
GROUP 4     
endolysin [E. faecium E1039] 394 ZP_06675756.1 
endolysin [E. faecium E1039] 425 ZP_06674744.1 
GROUP 5     
PlyP100 [E. faecalis HIP11704] 322 ZP_05566775.1 
endolysin [E. faecalis Merz96] 322 ZP_05564324.1 
endolysin [E. faecalis R712] 368 ZP_06628454.1 
endolysin [E. faecalis S613] 368 ZP_06632418.1 
endolysin [E. faecalis DS5] 322 ZP_05561234.1 
endolysin [E. faecalis T8] 351 ZP_05557995.1 
endolysin [E. faecalis V583] 368 NP_815207.1 
endolysin [E. faecalis R712] 368 ZP_06628239.1 
endolysin [E. faecalis S613] 368 ZP_06633896.1 
endolysin [E. faecalis Fly1] 341 ZP_05579618.1 
GROUP 6     
amidase [E. faecalis TX0104] 374 ZP_03948603.1 
amidase [E. faecalis HH22] 374 ZP_03983131.1 
amidase [E. faecalis TX1322] 374 ZP_04434756.1 
endolysin [E. faecalis R712] 374 ZP_06629056.1 
endolysin [E. faecalis S613] 374 ZP_06632253.1 
endolysin [E. faecalis V583] 365 NP_815016.1 
endolysin [E. faecalis ATCC 29200] 374 ZP_04438946.1 
endolysin [E. faecalis TUSoD Ef11] 365 ZP_04647840.1 
endolysin [E. faecalis X98] 365 ZP_05599811.1 
endolysin [E. faecalis T8] 361 ZP_05558304.1 
endolysin [E. faecalis ATCC 4200] 352 ZP_05475717.1 
endolysin [E. faecalis JH1] 350 ZP_05573170.1 
endolysin [E. faecalis HIP11704] 345 ZP_05569483.1 
endolysin [E. faecalis Fly1] 345 ZP_05579809.1 
endolysin [E. faecalis Merz96] 345 ZP_05566285.1 
endolysin [E. faecalis AR01/DG] 345 ZP_05592904.1 
endolysin [E. faecalis DS5] 345 ZP_05562950.1 
GROUP 7     
amidase [E. faecium 1,141,733] 338 ZP_05666679.1 
amidase [E. faecium Com15] 339 ZP_05677833.1 
amidase [E. faecium 1,231,501] 338 ZP_05664801.1 
amidase [E. faecium E980] 339 ZP_06681905.1 
amidase [E. faecium 1,230,933] 339 ZP_05659803.1 
amidase [E. faecium U0317] 339 ZP_06702043.1 
amidase [E. faecium 1,231,408] 339 ZP_05673558.1 
   
  AA ACCESION # 
amidase [E. faecium Com15] 338 ZP_05678707.1 
amidase [E. faecium 1,231,410] 339 ZP_05671179.1 
amidase [E. faecium E980] 336 ZP_06683607.1 
amidase [E. faecium E1071] 339 ZP_06680220.1 
amidase, family 2 [E. faecium C68] 320 ZP_05832333.1 
amidase [E. faecium 1,230,933] 336 ZP_05659231.1 
amidase [E. faecium 1,231,502] 336 ZP_05662248.1 
amidase [E. faecium U0317] 336 ZP_06700224.1 
amidase [E. faecium 1,231,501] 338 ZP_05663923.1 
amidase [E. faecium 1,231,410] 321 ZP_05671689.1 
amidase, family 2 [E. faecium TC 6] 323 ZP_05924003.1 
amidase, family 2 [E. faecium D344SRF] 323 ZP_06447215.1 
amidase [E. faecium 1,231,502] 306 ZP_05663252.1 
amidase [E. faecium E1636] 308 ZP_06695864.1 
GROUP 8     
amidase, family 2 [E. faecium DO] 341 ZP_00602919.1 
amidase [E. faecium E1162] 341 ZP_06676885.1 
amidase [E. faecium 1,231,408] 341 ZP_05673081.1 
amidase [E. faecium 1,231,410] 323 ZP_05671663.1 
amidase, family 2 [E. faecium C68] 322 ZP_05833245.1 
amidase [E. faecium E1636] 310 ZP_06694650.1 
amidase [E. faecium 1,231,502] 291 ZP_05661451.1 
GROUP 9     
amidase [E. faecalis V583] 503 NP_814047.1 
amidase [E. faecalis HH22] 503 ZP_03985946.1 
amidase [E. faecalis T11] 503 ZP_05595649.1 
amidase [E. faecalis Fly1] 503 ZP_05578550.1 
amidase [E. faecalis TX0104] 503 ZP_03950088.1 
amidase [E. faecalis AR01/DG] 503 ZP_05594613.1 
amidase [E. faecalis Merz96] 503 ZP_05564795.1 
amidase, family 4 [E. faecalis R712] 503 ZP_06628637.1 
amidase, family 4 [E. faecalis S613] 503 ZP_06632633.1 
amidase, family 4 [E. faecalis T8] 503 ZP_05560568.1 
amidase [E. faecalis HIP11704] 503 ZP_05568347.1 
amidase [E. faecalis ATCC 4200] 503 ZP_05475182.1 
amidase [E. faecalis TX1322] 503 ZP_04435643.1 
amidase [E. faecalis X98] 503 ZP_05598533.1 
amidase [E. faecalis ATCC 29200] 501 ZP_04439231.1 
amidase [E. faecalis DS5] 503 ZP_05560989.1 
amidase [E. faecalis E1Sol] 503 ZP_05575902.1 
amidase [E. faecalis JH1] 503 ZP_05572849.1 
amidase [E. faecalis TUSoD Ef11] 501 ZP_04648145.1 
GROUP 10     
amidase [E. faecalis TX0104] 309 ZP_03948310.1 
amidase, family 4 [E. faecalis R712] 309 ZP_06630528.1 
amidase, family 4 [E. faecalis S613] 309 ZP_06633335.1 
GROUP 11     
amidase [E. faecalis T1] 663 ZP_05423074.1 
amidase [E. faecalis T11] 649 ZP_05596538.1 
amidase [E. faecalis Fly1] 652 ZP_05579285.1 
amidase [E. faecalis E1Sol] 649 ZP_05576670.1 
amidase [E. faecalis V583] 652 NP_815520.1 
amidase [E. faecalis TX0104] 652 ZP_03949059.1 
amidase [E. faecalis HH22] 652 ZP_03983681.1 
amidase, family 4 [E. faecalis R712] 652 ZP_06629298.1 
amidase, family 4 [E. faecalis S613] 652 ZP_06633447.1 
GROUP 12     
amidase [E. casseliflavus EC20] 655 ZP_05655421.1 
amidase [E. casseliflavus EC30] 650 ZP_05645789.1 
amidase [E. casseliflavus EC10] 650 ZP_05652119.1 
STAND ALONE PROTEINS     
1  amidase [E. gallinarum EG2] 703 ZP_05649621.1 
2  PlyV12 [phage phi1] 314 AAT01859.1 
3  amidase [E. casseliflavus EC20] 715 ZP_05656866.1 
4  amidase [phage phiEF24C] 289 YP_001504118.1 
5  amidase [phage EFAP-1] 328 YP_002727874.1 
6  endolysin [E. faecalis HH22] 270 ZP_03985506.1 
7  amidase [E. faecalis T3] 523 ZP_05503383.1 
Identities within groups are generally ≥ 90%. 
Exception: 1 89%; 
 Table 2.   Staphylococcal lysins 
 
 
 
 
AA 
 
 
ACCESSION # 
 GROUP 1     
putative lysin [Staphylococcus phage K] 495 YP_024461 
endolysin [Staphylococcus phage 812] 494 ABL87139 
endolysin [Staphylococcus phage GH15] 495 ADG26756 
 GROUP 2     
N-acetylmuramoyl-L-alanine amidase [S. epidermidis 
M23864:W2(grey)] 
487 ZP_06612943 
autolysin (N-acetylmuramoyl-L-alanine amidase) [S. caprae C87] 487 ZP_07841306 
autolysin (N-acetylmuramoyl-L-alanine amidase) [S. capitis SK14] 487 ZP_03614343 
 GROUP 3     
amidase [Staphylococcus phage 44AHJD] 250 NP_817310 
ORF009 [Staphylococcus phage 66] 250 YP_239469 
amidase [Staphylococcus phage SAP-2] 249 YP_001491539 
GROUP 4      
lytic enzyme [S. aureus subsp. aureus N315] 251 NP_375054 
autolysin [S.  aureus subsp. aureus MR1] 251 ZP_06859751 
lytic enzyme [S.  aureus subsp. aureus MW2] 251 NP_646703 
autolysin [S. aureus subsp. aureus MSSA476] 251 YP_043983 
gametolysin [S. aureus subsp. aureus A017934/97] 251 ZP_06376153 
N-acetylmuramoyl-L-alanine amidase [S. aureus subsp. aureus 
H19] 
251 ZP_06343995 
lytic enzyme (N-acetylmuramoyl-L-alanine amidase) 
[Staphylococcus prophage phiPV83] 
251 NP_061648 
ORF017 [Staphylococcus phage 42E] 251 YP_239884 
 GROUP 5     
hypothetical protein 44AHJD_11 [Staphylococcus phage 44AHJD] 479 NP_817306 
ORF004 [Staphylococcus phage 66] 487 YP_239474 
hypothetical protein SAP2_gp10 [Staphylococcus phage SAP-2] 1 478 YP_001491535 
GROUP 6      
amidase [Staphylococcus phage phi2958PVL] 484 YP_002268027 
amidase (peptidoglycan hydrolase) [Staphylococcus phage PVL] 484 NP_058463 
amidase [Staphylococcus phage tp310-1] 484 YP_001429893 
truncated amidase [S. aureus subsp. aureus MW2] 484 NP_646197 
amidase [S. aureus A6224] 484 ZP_05696927 
ORF006 [Staphylococcus phage 96] 484 YP_240259 
prophage amidase, putative [S. aureus subsp. aureus ED133] 484 ADI96879 
putative amidase [S. aureus subsp. aureus ED98] 484 YP_003282866 
amidase [Staphylococcus phage phiSLT] 484 NP_075522 
amidase [S. aureus subsp. aureus ST398] 484 CAQ48834 
77ORF005 [Staphylococcus phage 77] 484 NP_958622 
amidase [S. aureus subsp. aureus MRSA252] 484 YP_040898 
prophage L54a, amidase, putative [S. aureus subsp. aureus COL] 484 YP_185281 
prophage L54a, amidase, putative [S. aureus subsp. aureus 
CGS03] 
484 EFT84462 
amidase [Staphylococcus phage tp310-2] 484 YP_001429961 
amidase [S. aureus subsp. aureus MSSA476] 484 YP_043081 
putative endolysin [Staphylococcus phage phiSauS-IPLA35] 484 YP_002332423 
N-acetylmuramoyl-L-alanine amidase [S. aureus A10102] 484 ZP_06334988 
peptidoglycan hydrolase [Staphylococcus phage phi12] 484 NP_803355 
N-acetylmuramoyl-L-alanine amidase [ORF007 Staphylococcus 
phage 47] 
484 %YP_240025 
peptidoglycan hydrolase, putative [S. aureus subsp. aureus 132] 484 ZP_06378887 
amidase [S. aureus A6300] 484 ZP_05693770 
N-acetylmuramoyl-L-alanine amidase [S.  aureus A9765] 484 ZP_06329456 
amidase [S. aureus subsp. aureus 65-1322] 484 ZP_05604610 
ORF008 [Staphylococcus phage 3A] 484 YP_239959 
 GROUP 7     
amidase [Staphylococcus phage CNPH82] 460 YP_950628 
phage amidase [Staphylococcus phage PH15] 460 YP_950690 
bacteriophage amidase [S. epidermidis M23864:W1] 2 460 ZP_04819028 
GROUP 8      
CHAP domain-containing protein [S. aureus subsp. aureus JH9] 470 YP_001246290 
bacteriophage amidase [S. aureus subsp. aureus 
USA300_TCH959] 
473 ZP_04865682 
phage amidase [S. aureus subsp. aureus 132] 470 ZP_06378624 
phage amidase [S. aureus subsp. aureus MR1] 470 ZP_06859762 
phage amidase [S. aureus subsp. aureus ED98] 470 YP_003281797 
CHAP domain-containing protein [S. aureus A6300] 470 ZP_05694219 
similar to phage phi PVL amidase [Staphylococcus phage phiETA] 470 NP_510959 
amidase [Staphylococcus phage phiETA2] 470 YP_001004328 
amidase [Staphylococcus phage phiETA3] 470 YP_001004396 
ORF007 [Staphylococcus phage 71] 470 YP_240407 
 GROUP 9     
Autolysin (S. aureus) 3 481 LYTA_STAAU 
amidase [Staphylococcus phage 80alpha] 4 481 AAB39699 
phage amidase [S. aureus subsp. aureus str. Newman] 481 YP_001332073 
amidase [S. aureus A9719] 486 ZP_05684021 
N-acetylmuramoyl-L-alanine amidase [S. aureus subsp. aureus 484 ZP_06324909 
D139] 
N-acetylmuramoyl-L-alanine amidase [S. aureus A9765] 484 ZP_06327634 
ORF007 [Staphylococcus phage 29] 481 YP_240560 
autolysin [S. aureus subsp. aureus NCTC 8325] 481 YP_500516 
Autolysin, hypothetical phage protein [S. aureus subsp. aureus 
TW20] 
481 CBI48272 
amidase [S. aureus subsp. aureus Mu50] 481 NP_371437 
ORF006 [Staphylococcus phage 88] 481 YP_240699 
endolysin [Staphylococcus phage phiMR11] 481 YP_001604156 
putative cell wall hydrolase [Staphylococcus phage phiMR25] 481 YP_001949866 
N-acetylmuramoyl-L-alanine amidase [S. aureus subsp. aureus 
C427] 
484 ZP_06327377 
N-acetylmuramoyl-L-alanine amidase [S. aureus subsp. aureus 
JH9] 
481 YP_001246457 
ORF007 [Staphylococcus phage 55] 481 YP_240484 
N-acetylmuramoyl-L-alanine amidase [S. aureus A6300] 486 ZP_05693156 
ORF007 [Staphylococcus phage 69] 481 YP_239596 
ORF007 [Staphylococcus phage 52A] 481 YP_240634 
N-acetylmuramoyl-L-alanine amidase [S. aureus subsp. aureus 
MN8] 
481 ZP_06948777 
ORF006 [Staphylococcus phage 92] 481 YP_240773 
autolysin [S. aureus subsp. aureus JKD6009] 481 ZP_03566881 
phage amidase [S. aureus A9635] 484 ZP_05687279 
phage-related amidase [S. aureus subsp. aureus CGS00] 481 EFU23738 
Autolysin (N-acetylmuramoyl-L-alanine amidase) [S. aureus 
subsp. aureus ST398] 
481 CAQ49916 
endolysin [Staphylococcus phage phiSauS-IPLA88] 486 YP_002332536 
 GROUP 10     
cell wall hydrolase [Staphylococcus phage 11] 632 NP_803302 
ORF004 [Staphylococcus phage 69] 632 YP_239591 
cell wall hydrolase [Staphylococcus phage phiNM] 632 YP_874009 
cell wall hydrolase [Staphylococcus phage TEM126] 632 ADV76510 
autolysin [S. aureus A9765] 632 ZP_06327630 
mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase [S. 
aureus subsp. aureus JH9] 
632 YP_001246286 
mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase [S. 
aureus A8115] 
632 ZP_05690673 
mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase [S. 
aureus subsp. aureus CGS03] 
589 EFT84342 
phage N-acetylglucosamidase [S. aureus subsp. aureus CGS00] 632 EFU23742 
ORF004 [Staphylococcus phage 85] 632 YP_239746 
phage N-acetylglucosamidase [S. aureus subsp. aureus str. 
Newman] 
632 YP_001331343 
cell wall hydrolase [S. aureus subsp. aureus Mu50] 632 NP_371433 
cell wall hydrolase [Staphylococcus phage phiETA2] 632 YP_001004324 
cell wall hydrolase [Staphylococcus phage SAP-26] 632 YP_003857090 
putative tail-associated cell wall hydrolase [Staphylococcus 
phage phiMR25] 
632 YP_001949862 
mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase [S. 
aureus subsp. aureus D139] 
632 ZP_06324913 
mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase [S. 
aureus subsp. aureus C427] 
632 ZP_06327381 
lyz  [Staphylococcus phage 80alpha] 632 YP_001285381 
   
ORF004 [Staphylococcus phage 53] 632 YP_239671 
phage-related cell wall hydrolase [S. aureus RF122]5 634 YP_417168 
putative peptidoglycan hydrolase [Staphylococcus phage 
phiSauS-IPLA88] 6 
634 YP_002332533 
 GROUP 11     
ORF004 [Staphylococcus phage 71] 624 YP_240403 
similar to phage phi187 cell hydrolase Ply187 [Staphylococcus 
phage phiETA] 
624 NP_510955 
mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase [S. 
aureus subsp. aureus 132] 
624 ZP_06378620 
mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase [S. 
aureus subsp. aureus str. CF-Marseille] 
624 ZP_04837774 
conserved hypothetical protein [S. aureus A9635] 624 ZP_05687283 
ORF004 [Staphylococcus phage 55] 624 YP_240479 
cell wall hydrolase [Staphylococcus phage phiETA3] 624 YP_001004392 
tail tip protein [Staphylococcus phage phiMR11] 624 YP_001604152 
ORF004 [Staphylococcus phage ROSA] 624 YP_240329 
ORF004 [Staphylococcus phage 96] 624 YP_240255 
ORF004 [Staphylococcus phage 88] 624 YP_240695 
ORF004 [Staphylococcus phage 29] 624 YP_240556 
ORF005 [Staphylococcus phage X2] 624 YP_240843 
mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase [S. 
aureus subsp. aureus JKD6009] 
624 ZP_03566885 
hypothetical protein HMPREF0776_1895 [S. aureus subsp. 
aureus USA300_TCH959] 
624 ZP_04865678 
mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase [S. 
aureus subsp. aureus H19] 
 
624 ZP_06343859 
 GROUP 12     
hydrolase [Staphylococcus phage PH15] 7 633 YP_950686 
hydrolase [S. epidermidis BCM-HMP0060] 8 607 ZP_04824942 
amidase [Staphylococcus phage CNPH82] 633 YP_950623 
N-acetylmuramoyl-L-alanine amidase [S. epidermidis 
M23864:W2(grey)] 9 
635 ZP_06614671 
GROUP 13      
bifunctional autolysin Atl/ N-acetylmuramoyl-L-alanine amidase/ 
endo-beta-N-acetylglucosaminidase [S. pseudintermedius 
HKU10-03] 10 
629 YP_004148762 
ORF002 [Staphylococcus phage 187] 628 YP_239513 
cell wall hydrolase Ply187 [Staphylococcus phage 187] 628 CAA69022 
 Stand alone proteins     
1  Lysostaphin [S. simulans] 389 AAA26655 
2  Endolysin [Staphylococcus phage 812] 284 ABL87142 
3  Lytic enzyme, amidase  [S. aureus] 426 ACZ59017 
4  Endolysin [Staphylococcus phageSA4] 267 ADR02788 
5  Glycyl-glycine endopeptidase ALE1 362 ALE1-STACP 
6  Lysine [Bacteriophage phi WMY] 477 BAD83402 
7  Phage amidase [Staphylococcus aureus subsp. aureus TW20] 500 CBI50050 
8  lysostaphin 480 LSTP_STAST 
9  Phage N-acetylmuramoyl-L-alanine amidase [S. lugdunensis 
HKU09-01] 
488 YP_003472450 
10  lysostaphin [S. simulans bv. staphylolyticus] 452 YP_003505772 
11  Autolysin [S. pseudintermedius HKU10-03] 251 YP_004148764 
12  prophage, amidase, putative [S. epidermidis RP62A] 463 YP_189215 
13  ORF015 [Staphylococcus phage Twort] 467 YP_238716 
14  ORF021 [Staphylococcus phage 85] 213 YP_239752 
15  ORF018 [Staphylococcus phage 85] 237 YP_239755 
16  ORF007 [Staphylococcus phage 2638A] 486 YP_239818 
17  ORF004 [Staphylococcus phage 37] 639 YP_240099 
18  ORF006 [Staphylococcus phage 37] 481 YP_240103 
19  ORF003 [Staphylococcus phage EW] 630 YP_240176 
20  ORF007 [Staphylococcus phage EW] 482 YP_240182 
21  ORF018 [Staphylococcus phage X2] 213 YP_240847 
22  ORF019 [Staphylococcus phage X2] 210 YP_240849 
23  amidase (peptidoglycan hydrolase) [S. haemolyticus 
JCSC1435] 
464 YP_253663 
24  N-acetylmuramoyl-L-alanine amidase [S. haemolyticus 
JCSC1435] 
494 YP_254248 
25  hypothetical protein SH2336 [S. haemolyticus JCSC1435] 647 YP_254251 
26  mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase 
[S.  capitis SK14] 
626 ZP_03614366 
27  autolysin [S.  warneri L37603] 477 ZP_04679079 
28  possible N-acetylmuramoyl-L-alanine amidase [S. epidermidis 
BCM-HMP0060] 
574 ZP_04824947 
29  conserved hypothetical protein [S. aureus subsp. aureus 
E1410] 
325 ZP_05610313 
30  peptidoglycan hydrolase [S. aureus A9299] 405 ZP_05688267 
31  amidase [S. aureus A9299] 405 ZP_05688584 
32  conserved hypothetical protein [S. aureus A6300] 494 ZP_05694215 
33  bacteriophage amidase [S. epidermidis M23864:W2(grey)] 467 ZP_06614678 
34  N-acetylmuramoyl-L-alanine amidase [S. aureus A8819] 394 ZP_06817547 
35  petidoglycan hydrolase, putative [S. aureus subsp. aureus 
MR1] 
392 ZP_06859771 
36  N-acetylmuramoyl-L-alanine amidase [S. aureus A8796] 419 ZP_06930779 
37  N-acetylmuramoyl-L-alanine amidase [S. aureus subsp. 
aureus ATCC BAA-39] 
564 ZP_07361756 
Identities within groups are generally ≥ 90%. Exceptions: 
1 89%; 2 87%; 3 89%; 4 89%; 5 88%; 6 88%; 7 89%; 8 87%; 9 
86%; 10 84%; 
 
Table 3.   Streptococcal lysins   
 
 
AA 
 
ACCESSION # 
GROUP 1 a   
Cpl-1 [S. pneumoniae] 339 NP_044837.1 
Cpl-9 [S. pneumoniae] 339 P19386.1 
   
GROUP 1 b   
PH10 lysin [S. oralis] 334 YP_002925184.1 
   
GROUP 1 c   
Cpl-7 [S. pneumoniae] 342 P19385.1 
   
GROUP 2 a   
autolysin [S. pneumoniae SP3-BS71] 318 ZP_01819152.1 
lytic amidase [S. pneumoniae SP195] 318 ZP_02714370.1 
autolysin [S. pneumoniae SP11-BS70] 318 ZP_01824138.1 
lytic amidase [S. pneumoniae CDC1873-00] 318 ZP_02708645.1 
autolysin [S. pneumoniae SP19-BS75] 318 ZP_01832999.1 
lytic amidase [S. pneumoniae 670-6B] 318 YP_003880285.1 
lytic amidase [S. pneumoniae Hungary19A-6] 318 YP_001693491.1 
autolysin [S. pneumoniae SP6-BS73] 318 ZP_01821560.1 
autolysin [S. pneumoniae AP200] 318 YP_003875665.1 
MM1 lysin [S. pneumoniae] 318 NP_150182.1 
lytic amidase [S. pneumoniae SP195] 318 ZP_02712971.1 
VO1 amidase [S. pneumoniae] 318 CAD35393.1 
HB-3 amidase [S. pneumoniae]  318 P32762.1 
lytic amidase [S. pneumoniae CDC3059-06] 318 ZP_02718952.1 
lytic amidase [S. pneumoniae 70585] 318 YP_002739391.1 
lytic amidase [S. pneumoniae SP-BS293] 318 ZP_07345341.1 
lytic amidase [S. pneumoniae P1031] 318 YP_002737318.1 
autolysin [S. pneumoniae SP23-BS72] 318 ZP_01835850.1 
   
GROUP2 b   
autolysin [S. pneumoniae] 313 AAK29073.1 
autolysin [S. pneumoniae TIGR4] 318 NP_346365.1 
amidase [S. pneumoniae R6] 318 NP_359346.1 
putative amidase [S. pneumoniae INV104] 318 CBW37351.1 
autolysin [S. pneumoniae SP3-BS71] 318 ZP_01818711.1 
VO1 amidase [S. pneumoniae 8249] 318 CAD35389.1 
LytA amidase [S. pneumoniae] 318 CAJ34409.1 
LytA amidase [S. pneumoniae] 318 CAJ34410.1 
autolysin [S. pneumoniae 670-6B] 318 YP_003880176.1 
autolysin [S. pneumoniae] 313 AAK29074.1 
autolysin [S. pneumoniae CDC1087-00] 318 ZP_02711922.1 
Autolysin [S. pneumoniae] 313 CBE65469.1 
LytA autolysin [S. pneumoniae] 302 CAB53774.1 
Autolysin [S. pneumoniae SP11-BS70] 318 ZP_01825916.1 
LytA autolysin [S. pneumoniae] 302 CAB53770 
autolysin [S. pneumoniae 670-6B] 318 YP_003878279.1 
autolysin [S. pneumoniae SP14-BS69] 318 ZP_01828965.1 
autolysin [S. pneumoniae JJA] 318 YP_002736862.1 
   
GROUP 2 c   
LytA amidase [s. pneumoniae] 316 CAD12111.1 
amidase [S. mitis SK597] 316 ZP_07640915.1 
LytA amidase [s. pneumoniae] 316 CAD12115.1 
LytA amidase [S. pneumoniae sp. 1504] 316 CAJ34416.1 
LytA amidase [s. pneumoniae] 316 CAD12112.1 
LytA amidase [S. pneumoniae] 316 CAD12116.1 
LytA amidase [S. pneumoniae] 316 CAD12106.1 
LytA amidase [S. pseudopneumoniae] 316 CAJ34411.1 
LytA amidase [S. pneumoniae] 316 CAD12108.1 
LytA amidase [S. pneumoniae sp. 578] 316 CAJ34413.1 
LytA amidase [S. pneumoniae sp. 3072] 316 CAJ34420.1 
LytA amidase [S. pneumoniae] 316 CAD12113.1 
LytA amidase [S. pneumoniae] 316 CAD12110.1 
LytA amidase [S. pneumoniae sp. 2410] 316 CAJ34419.1 
LytA101 [S. pneumoniae] 316 AAB23082.1 
Autolysin [S. mitis] 300 CAB76388.1 
Autolysin [Streptococcus sp.] 300 CAB76391.1 
LytA amidase [S. pneumoniae] 316 CAD12114.1 
Autolysin [Streptococcus sp.] 300 CAB76389.1 
Autolysin [Streptococcus sp.] 300 CAB76392.1 
LytA amidase [S. pneumoniae sp. 1237] 316 CAJ34414.1 
Autolysin [Streptococcus sp.] 300 CAB76394.1 
LytA amidase [S. pneumoniae] 316 CAD12109.1 
LytA amidase [S. pneumoniae] 316 CAD12107.2 
Autolysin [Streptococcus sp.] 300 CAB76390.1 
   
GROUP 2 d   
LytA amidase [S. mitis B6] 318 YP_003445618.1 
LytA-like amidase [S. mitis] 318 CAF02035.1 
EJ-1 lysin [S. pneumoniae] 316 NP_945312.1 
   
GROUP 3 a   
putative lysin [S. pyogenes phage 315.2] 402 NP_664726.1 
putative amidase [S. pyogenes phage 315.1] 401 NP_664535.1 
phage-associated lysin [S. pyogenes NZ131] 402 YP_002286426.1 
spyM18_0777 [S. pyogenes MGAS8232] 401 NP_606945.1 
phage-associated lysin [Streptococcus phage 9429.1] 404 YP_596324.1 
spyM18_1750 [S. pyogenes MGAS8232] 401 NP_607778.1 
amidase [S. pyogenes MGAS10394] 401 YP_060660.1 
putative phage amidase [S. pyogenes str. Manfredo] 401 YP_001128106.1 
Spy_1438 [S. pyogenes M1 GAS] 401 NP_269522.1 
spyM18_1448 [S. pyogenes MGAS8232] 401 NP_607527.1 
amidase [S. pyogenes ATCC 10782] 401 ZP_07461342.1 
Amidase [S. pyogenes ATCC10782] 401 ZP_07460525.1 
   
GROUP 3 b   
315.4 lysin [S. pyogenes phage phiNIH1.1] 400 NP_438163.1 
Phage associated lysin [S. pyogenes MGAS10394] 400 YP_059383.1 
370.1 lysin [S. pyogenes] 400 NP_268942.1 
amidase [S. pyogenes ATCC 10782] 400 ZP_07461599.1 
lysin [S. dysgalactiae subsp. equisimilis GGS_124] 400 YP_002996819.1 
P9 lysin [S. equi phage P9] 400 YP_001469230.1 
   
GROUP 3 c   
315.6 lysin [S. pyogenes MGAS315] 244 NP_665215.1 
SPs0453 [S. pyogenes SSI-1] 226 NP_801715.1 
SPs1121 [S. pyogenes SSI-1] 226 NP_802383.1 
   
GROUP 3 d   
phage-associated lysin [S. equi subsp. equi 4047] 404 YP_002745608.1 
phage amidase [S. equi subsp. equi 4047] 403 YP_002746965.1 
   
GROUP 3 e   
phage-associated lysin [S. pyogenes MGAS5005] 398 YP_282779.1 
Phage 2096.1 lysin [group A Streptococcus] 398 YP_600196.1 
Phage amidase [S. equi subsp. equi 4047] 1 398 YP_002746181.1 
   
GROUP 3 f   
spyM18_1242 [S. pyogenes MGAS8232] 161 NP_607353.1 
   
GROUP 3 g   
Phage-associated lysin [S. pyogenes MGAS10394] 213 YP_060304.1 
   
GROUP 4   
putative phage lysin [S. pyogenes phage 315.5] 254 NP_665110.1 
SpyoM01000009 [S. pyogenes M49 591] 251 ZP_00366664.1 
phage-associated lysin [S. pyogenes MGAS5005] 254 YP_282364.1 
   
GROUP 5 a   
Phi3396 lysin [S. dysgalactiae subsp. equisimilis] 253 YP_001039943.1 
Phage NZ131.2 lysin [S. pyogenes] 249 YP_002285797.1 
Phage-associated lysin [S. pyogenes MGAS10394] 250 YP_060862.1 
   
GROUP 5 b   
Phage-associated lysin [S. pyogenes MGAS10394] 203 YP_060515.1 
   
GROUP 6 a   
phage 9429.2 lysin [S. pyogenes] 373 YP_596581.1 
   
GROUP 6 b   
B30 lysin [S. agalactiae] 445 AAN28166.2 
49.7 kDA protein [S. equi] 444 AAF72807.1 
putative lysin [S. pyogenes phage 370.3] 444 NP_269184.1 
PlyGBS [S. agalactiae phage NCTC11261] 443 AAR99416.1 
phage-associated lysin [S. pyogenes MGAS6180] 444 YP_280438.1 
prophage LambdaSa03 endolysin [S. agalactiae] 443 YP_329285.1 
49.7 kDa protein [S. agalactiae 18RS21] 447 ZP_00780878.1 
putative phage lysin [S. pyogenes strain Manfredo] 444 YP_001128574.1 
phage lysin [S. equi subsp. equi 4047] 444 YP_002747253.1 
   
GROUP 7   
LambdaSa1 lysin [S. agalactiae 2603V/R] 239 NP_687631.1 
Endolysin [S. agalactiae H36B] 248 ZP_00782522.1 
   
GROUP 8 a   
putative amidase [S. pyogenes phage 315.3] 404 NP_664900.1 
putative amidase [S. pyogenes MGAS8232] 405 NP_606641.1 
phage protein [S. pyogenes MGAS10750] 405 YP_602773.1 
putative phage lysin [S. pyogenes str. Manfredo] 402 YP_001128256.1 
   
GROUP 8 b   
LambdaSa2 lysin [S. dysgalactiae subsp. equisimilis 
GGS_124] 
449 YP_002997317.1 
   
GROUP 8 c   
LambdaSa2 lysin [S. agalactiae 2603V/R] 468 NP_688827.1 
   
GROUP 8 d   
SMP lysin [S. suis] 481 YP_950557.1 
   
GROUP 9 a   
Cell wall binding repeat family protein [S. mitis SK321] 568 ZP_07643272.1 
Cell wall binding repeat family protein [S. mitis SK597] 570 ZP_07641594.1 
endo-beta-N-acetylglucosaminidase [S. mitis NCTC 12261] 568 ZP_07645063.1 
LytB [S. mitis] 568 ACO37163.1 
LytB [S. mitis B6] 570 YP_003446078.1 
   
GROUP 9 b   
endo-beta-N-acetylglucosaminidase [S. pneumoniae 
70585] 
702 YP_002740268.1 
endo-beta-N-acetylglucosaminidase [S. pneumoniae G54] 702 YP_002037600.1 
endo-beta-N-acetylglucosaminidase [S. pneumoniae 
Hungary19A-6] 
702 YP_001694410.1 
endo-beta-N-acetylglucosaminidase [S. pneumoniae 
P1031] 
702 YP_002738134.1 
endo-beta-N-acetylglucosaminidase [S. pneumoniae 
Taiwan19F-14] 
702 YP_002742657.1 
endo-beta-N-acetylglucosaminidase [S. pneumoniae 
BS397] 
702 ZP_07350631.1 
   
GROUP 9 c   
endo-beta-N-acetylglucosaminidase [S. pneumoniae SP-
BS293] 
614 ZP_07345852.1 
endo-beta-N-acetylglucosaminidase [S. pneumoniae] 614 AAK19156.1 
endo-beta-N-acetylglucosaminidase [S. pneumoniae 
CDC1087-00] 
614 ZP_02710425.1 
endo-beta-N-acetylglucosaminidase [S. pneumoniae 
INV104] 
614 CBW36509.1 
LytB [Spneumoniae AP200] 614 YP_003876588.1 
   
GROUP 9 d   
endo-beta-N-acetylglucosaminidase [S. pneumoniae 
CGSP14] 
677 YP_001835658.1 
   
GROUP 9 e   
endo-beta-N-acetylglucosaminidase [S. pneumoniae CCRI 
1974] 
658 ZP_04525138.1 
endo-beta-N-acetylglucosaminidase [S. pneumoniae 
CDC0288-04] 
658 ZP_02715197.1 
endo-beta-N-acetylglucosaminidase [S. pneumoniae 
CDC3059-06] 
658 ZP_02718537.1 
endo-beta-N-acetylglucosaminidase [S. pneumoniae JJA] 658 YP_002735981.1 
endo-beta-N-acetylglucosaminidase [S. pneumoniae 
SP23-BS72] 
658 ZP_01834875.1 
endo-beta-N-acetylglucosaminidase [S. pneumoniae MLV-
016] 
658 ZP_02721563.1 
endo-beta-N-acetylglucosaminidase [S. pneumoniae 
TIGR4] 
658 NP_345446.1 
endo-beta-N-acetylglucosaminidase [S. pneumoniae SP3-
BS71] 
658 ZP_01817975.1 
   
GROUP 9 f   
endo-beta-N-acetylglucosaminidase [S. pneumoniae 
INV200] 
721 CBW34519.1 
endo-beta-N-acetylglucosaminidase [S. pneumoniae R6] 721 NP_358461.1 
endo-beta-N-acetylglucosaminidase [S. pneumoniae 
TCH8431/19A] 
721 YP_003724965.1 
   
GROUP 10   
endo-beta-N-acetylglucosaminidase [S. mitis ATCC6249] 750 ZP_07462509.1 
endo-beta-N-acetylglucosaminidase [S. sanguinis 
ATCC49296] 
750 ZP_07887886.1 
endo-beta-N-acetylglucosaminidase [Streptococcus sp. 
oral taxon str. 73H25AP] 
750 ZP_07458768.1 
   
GROUP 11 a   
Lysozyme [S. mitis NCTC 12261] 525 ZP_07644807.1 
LytC Cpb13 [S. mitis B6] 536 YP_003446665.1 
   
GROUP 11 b   
Cell wall binding protein [S. mitis SK564] 504 ZP_07642782.1 
Cell wall binding protein [S. mitis SK597] 504 ZP_07641292.1 
Cell wall binding protein [S. mitis SK321] 493 ZP_07642984.1 
   
GROUP 11 c   
Lysozyme [S. pneumoniae SP3-BS71] 270 ZP_01818179.1 
   
GROUP 11 d   
1,4-beta-N-acetylmuramidase [S. pneumoniae CDC1873-
00] 
490 ZP_02708500.1 
1,4-beta-N-acetylmuramidase [S. pneumoniae P1031] 490 YP_002738710.1 
1,4-beta-N-acetylmuramidase [S. pneumoniae SP11-BS70] 490 ZP_01824964.1 
1,4-beta-N-acetylmuramidase [S. pneumoniae SP9-BS68] 490 ZP_01822918.1 
1,4-beta-N-acetylmuramidase [S. pneumoniae 70585] 490 YP_002740840.1 
1,4-beta-N-acetylmuramidase [S. pneumoniae CDC1087-
00] 
490 ZP_02711346.1 
1,4-beta-N-acetylmuramidase [S. pneumoniae 
TCH8431/19A] 
501 YP_003725251.1 
1,4-beta-N-acetylmuramidase [S. pneumoniae R6] 501 NP_359024.1 
1,4-beta-N-acetylmuramidase [S. pneumoniae] 492 AAK19157.1 
1,4-beta-N-acetylmuramidase [S. pneumoniae SP18-BS74] 490 ZP_01831146.1 
ATP dependent protease [S. pneumoniae SP23-BS72] 490 ZP_01836005.1 
ATP dependent protease [S. pneumoniae SP6-BS73] 490 ZP_01820060.1 
endo-beta-N-acetylglucosaminidase [S. pneumoniae G54] 490 YP_002038205.1 
Lysozyme [S. pneumoniae Taiwan 19F-14] 493 YP_002742915.1 
Lysozyme [S. pneumoniae BS455] 490 ZP_07341428.1 
Lysozyme [S. pneumoniae CGSP14] 501 YP_001836276.1 
LytC autolysin [S. pneumoniae] 501 CAA08765.1 
Putative choline binding glycosyl hydrolase [S. 
pneumoniae INV104] 
490 CBW37026.1 
Putative choline binding glycosyl hydrolase [S. 
pneumoniae ATCC700669] 
490 YP_002511487.1 
SpneCMD 07616 [S. pneumoniae str. Canada MDR 19F] 490 ZP_06964203.1 
SpneT 0200379 [S. pneumoniae TIGR4] 490 ZP_01409152.1 
   
GROUP 11 e   
1,4-beta-N-acetylmuramidase [S. pneumoniae SP14-BS69] 311 ZP_01828088.1 
   
GROUP 11 f   
Lysozyme [S. pneumoniae SP19-BS75] 227 ZP_01833670.1 
   
GROUP 12 a   
Pal [S. pneumoniae phage DP-1] 296 O03979.1 
   
GROUP 12 b   
gp56 [Streptococcus phage SM1] 295 NP_862895.1 
   
GROUP 13 a   
S3b lysin [S. thermophilus] 2 206 + 
82 5 
AAF24749.1 
DT1 lysin [S. thermophilus] 200 + 
75 5 
NP_049413.1 + 
NP_049415.2 
ALQ13.2 lysin [S. thermophilus] 200 + 
75 5 
YP_003344870.1+ 
YP_003344872.1 
Orf28 [S. thermophilus phage 858] 200 + 
75 5 
YP_001686822.1+
YP_001686825.1 
Phage 2972 lysin [S. thermophilus] 3 199 + 
75 5 
YP_238509.1 + 
YP_238512.1 
   
GROUP 13 b   
Putative phage PH15 endolysin [S. gordonii] 283 YP_001974380.1 
   
GROUP 13 c   
Abc2 lysin [S. thermophilus] 281 YP_003347431.1 
ORF44 [S. thermophilus phage 7201] 281 NP_038345.1 
Phage 5093 lysin [S. thermophilus CSK939] 281 YP_002925118.1 
Phage O1205 p51 [S. thermophilus CNRZ1205] 4 281 NP_695129.1 
   
GROUP 13 d   
Sfi11 lysin [S. thermophilus] 288 NP_056699.1 
Sfi18 lysin [S. thermophilus] 288 AAF63073.1 
Sfi19 lysin [S. thermophilus] 288 NP_049942.1 
Sfi21 lysin [S. thermophilus] 288 NP_049985.1 
   
GROUP 13 e   
STRINF 01560 [S. infantarius subsp. infantarius ATCC BAA-
102] 
281 ZP_02920679.1 
   
STAND ALONE PROTEINS   
1  700P1 lysin [S. uberis] 236 ABB02702.1 
2  Phage M102 gp19S [S. mutans] 273 YP_002995476.1 
3  PlyC [Group A Streptococcus phage C1] 465 + 
72 6 
NP_852017.2 
Identities within groups are generally ≥ 90%. Exceptions: 
1 88%; 2 88%; 3 84%; 4 86%; 
5 Encoded by two coding regions separated by an intron 
6 Multimeric protein consisting of two gene products 
Table 4.  Summary of in vivo studies with phage endolysin as antimicrobial.  
Bacteria Phage Endolysin Reference 
Streptococcus pneumoniae Cp-1 Cpl-1 Loeffler et al., 2001 
    Loeffler et al., 2003 
    Loeffler & Fischetti, 2003 
    Jado et al., 2003 
    Entenza et al., 2005 
    McCullers et al., 2007 
    Grandgirard et al., 2008 
Streptococcus pneumoniae Dp-1 PAL Loeffler & Fischetti, 2003 
      Jado et al., 2003 
Streptococcus pyogenes C1 C1* Nelson et al., 2001 
Streptococcus agalactiae NCTC 11361 PlyGBS Cheng et al., 2005 
Bacillus anthracis γ PlyG Schuch et al., 2002 
  N/A** PlyPH Yoong et al., 2006 
Staphylococcus aureus MR11 MV-L Rashel et al., 2007 
  N/A*** ClyS Daniel et al., 2010 
 Bacteriophage K CHAPk Fenton et al., 2010 
  GH15 LysGH15 Gu et al., 2011 
*Renamed PlyC according to (Nelson et al., 2006)   
**This endolysin was amplified from a prophage of the Bacillus anthracis Ames strain  
***Chimeric construct from the bacteriophage Twort and PhiNM3 endolysins 
 
 
 
 
 
